Juanetes

Preclinical and some clinical evidence supports cardioprotective effects of acai through antioxidant, anti-inflammatory, lipid-modulating, and vasodilatory mechanisms. Human trials show modest improvements in cholesterol, vascular function, and inflammation biomarkers relevant to cardiovascular risk. No large RCT has specifically assessed cardiovascular event outcomes.

An 8-week RCT in humans with elevated LDL found adzuki bean polyphenol extract significantly raised HDL-C compared to placebo. Animal studies show adzuki bean extract reduces systolic blood pressure, ACE activity, and aortic lesion in hypertensive rats. High dietary fiber content also supports cardiovascular health through established cholesterol-lowering mechanisms.

Ajoene contributes to cardiovascular protection through its antiplatelet activity, inhibition of arterial smooth muscle cell proliferation, and suppression of cholesterol biosynthesis via HMG-CoA reductase inhibition in hepatocyte models. These mechanisms are relevant to atherosclerosis and thrombotic cardiovascular events. Evidence is primarily from in vitro and animal studies.

Preclinical studies document antihypertensive effects (calcium channel blockade via thymol), lipid-lowering effects (reduced total cholesterol, LDL, triglycerides; increased HDL in animal models), and antiplatelet activity. A human RCT (n=99) examined ajwain as adjunct therapy in hypertension. Taken together, multiple cardiovascular pharmacological properties have been scientifically characterized.

A. muciniphila abundance is inversely associated with hypertension and cardiovascular risk markers in humans. Clinical supplementation reduced total cholesterol in an RCT, and animal models document reduced atherosclerotic lesion progression and vascular endothelial inflammation. However, direct cardiovascular endpoint trials in humans have not yet been completed.

ALA has documented cardioprotective effects supported by prospective studies and multiple RCTs. It modestly lowers LDL cholesterol and triglycerides, reduces systolic blood pressure, and exerts anti-platelet and anti-inflammatory actions. Major dietary trials including the Lyon Diet Heart Study and PREDIMED showed reduced cardiovascular events in high-ALA diets.

Alpha-Lipoic Acid (ALA) has human clinical evidence supporting several cardiovascular benefits, primarily through antioxidant and anti-inflammatory mechanisms. RCTs demonstrate significant improvements in endothelial function, reductions in inflammatory markers (CRP, IL-1, TNF-α), and modest benefits in heart failure patients. Evidence is promising but still limited by small sample sizes and short study durations, with no consensus on optimal dosing.

Alfalfa's saponins, flavonoids, and phytosterols collectively support cardiovascular health by lowering LDL cholesterol and triglycerides, increasing HDL, and providing antioxidant and anti-inflammatory effects. Primate studies demonstrated regression of atherosclerotic lesions with alfalfa supplementation. Human clinical evidence is limited but supportive.

Algal oil DHA reduces cardiovascular risk through triglyceride lowering, improvement of lipoprotein particle size, modest blood pressure reduction, and anti-inflammatory and antiplatelet effects. A meta-analysis of 11 RCTs (n=485) demonstrated that algal DHA significantly lowers serum triglycerides and raises HDL-cholesterol. At 1–2 g/day, algal DHA reduces triglycerides by up to 26%.

Almonds have an FDA-qualified health claim for reducing coronary artery disease risk. Multiple RCTs and meta-analyses demonstrate favorable effects on LDL cholesterol, diastolic blood pressure, endothelial function, and oxidized LDL—all established cardiovascular risk factors. The evidence base is among the largest for any single food ingredient.

Multiple clinical trials demonstrate D-ribose improves diastolic function, exercise tolerance, and quality of life in patients with coronary artery disease and congestive heart failure by restoring depleted myocardial ATP. Evidence is strongest in ischemic and failing hearts; effects in healthy hearts are undemonstrated.

Multiple independent prospective cohort studies find higher serum alpha-carotene inversely associated with cardiovascular disease mortality. A Japanese population-based follow-up study (N=3,061; ~12 years) found serum alpha-carotene significantly associated with lower CVD mortality risk. A large NHANES-based cross-sectional study (N=12,424) showed alpha-carotene in the highest quartile associated with 39% lower odds of prevalent CVD (OR=0.61, 95% CI 0.47–0.79). These associations are observational; no alpha-carotene-specific RCT for CVD outcomes exists.

AGIQ is characterized across multiple published reviews as possessing cardioprotective properties, including anti-anaphylactic cardiovascular effects (isoquercitrin, animal data), improved endothelial function (human RCT), and antioxidant protection of cardiac tissue. Direct human clinical trial evidence for AGIQ on specific cardiac outcomes (e.g., arrhythmia, heart failure) is not yet established.

Amaranth oil has been tested in a randomized placebo-controlled trial of 125 patients with coronary heart disease and hypertension, showing cardiovascular benefit when added to a low-salt diet. The grain and oil contribute multiple cardioprotective components: squalene, polyunsaturated fatty acids, antioxidant tocopherols, phytosterols, and ACE-inhibitory peptides. Multiple reviews identify amaranth as a potential dietary adjunct for cardiovascular risk reduction.

Anchovies are one of the most concentrated dietary sources of EPA and DHA, which have been extensively shown to reduce triglycerides, lower blood pressure, reduce arterial plaque, decrease platelet aggregation, and support heart rhythm. A meta-analysis of 38 RCTs confirmed omega-3 fatty acids reduce cardiovascular mortality and major adverse cardiac events.

Annatto-derived delta-tocotrienol has demonstrated cardiovascular benefits in clinical trials including reductions in total cholesterol, LDL, triglycerides, and inflammatory cytokines. A clinical study in hypercholesterolemic subjects found 250 mg/day reduced total cholesterol by 15%, LDL by 18%, and triglycerides by 14% within 4 weeks. Traditional use of annatto seeds as a cardiotonic is documented in indigenous South American medicine.

Multiple systematic reviews and meta-analyses confirm associations between apple intake and reduced cardiovascular disease risk. Apple polyphenols and pectin contribute to cholesterol reduction, blood pressure modulation, and endothelial function improvements documented in RCTs.

ACV has been studied as an agent addressing multiple cardiometabolic risk factors simultaneously: blood glucose, LDL cholesterol, triglycerides, and modest blood pressure effects. No direct cardiovascular endpoint trials (e.g., MI or stroke reduction) exist; evidence is restricted to surrogate markers. Meta-analyses confirm improvements in lipid and glycemic parameters relevant to cardiovascular risk.

Multiple pharmacological reviews cite cardioprotective activity as a primary documented effect of Prunus armeniaca. Apricot melanoidins have been shown to protect human endothelial cells against oxidative injury in cell-based studies. Clinical data on bitter apricot seeds demonstrate improvements in atherogenic lipid fractions. Dietary apricot provides potassium, fiber, and polyphenols with established cardiovascular benefits.

Multiple human RCTs and a meta-analysis of 5 trials (n=292) confirm argan oil supplementation significantly reduces total cholesterol, LDL-C, and triglycerides, and raises HDL-C. In dyslipidaemic patients it also reduced platelet aggregation, a key thrombotic risk factor.

Terminalia arjuna bark has been evaluated in multiple human clinical trials for cardiovascular conditions including chronic stable angina, heart failure, and dyslipidemia. Double-blind, placebo-controlled crossover studies demonstrate significant reductions in anginal frequency and improvements in exercise tolerance. Add-on trials in chronic heart failure patients on standard pharmacotherapy show improvements in left ventricular ejection fraction and functional class. The evidence base, while promising, is limited by small sample sizes and calls for larger, multi-centre RCTs.

Multiple controlled clinical trials and meta-analyses support Aronia melanocarpa's benefit for cardiovascular risk factors, including reductions in blood pressure, total cholesterol, LDL cholesterol, and triglycerides. A meta-analysis of 327 participants across controlled trials demonstrated that 6–8 weeks of daily supplementation significantly reduced systolic blood pressure and total cholesterol, especially in adults over 50.

Multiple RCTs and meta-analyses confirm artichoke leaf extract reduces total cholesterol, LDL, and triglycerides and raises HDL in hypercholesterolemic adults. A 2025 meta-analysis of multiple RCTs found significant reductions in total cholesterol (WMD −12.29 mg/dL) and LDL. One study in metabolic syndrome patients also showed improved carotid intima-media thickness after six months of ALE.

Ashitaba chalcone DMC protected mice from myocardial ischemia injury in a Nature Communications study. Ashitaba also reduces PAI-1 (a prothrombotic marker) in animal models of obesity and inflammation, and has antihypertensive and anti-hyperlipidemic properties in preclinical research. No human cardiac outcome trials exist.

Astaxanthin, a xanthophyll carotenoid, has human clinical evidence supporting cardiovascular benefits primarily through antioxidant and anti-inflammatory mechanisms. RCT-level data show favorable effects on HDL cholesterol and triglycerides, reduced inflammatory markers (CRP), and improved endothelial function. Pilot studies also indicate improvements in cardiac function and exercise tolerance in heart failure patients. Evidence is promising but limited by small sample sizes and short trial durations, and large-scale cardiovascular endpoint trials are still lacking.

Clinical studies and systematic reviews support astragalus improving cardiac function in heart failure, viral myocarditis, and ischemic heart disease. Patients with heart failure receiving 2.25 g astragalus twice daily alongside standard treatment showed greater improvements in cardiac function than standard treatment alone. Mechanisms include antioxidant, anti-inflammatory, antifibrotic, and calcium-regulatory actions on cardiomyocytes.

ATP disodium supplementation has demonstrated clinically relevant cardiovascular benefits in human trials, including improved heart rate variability recovery and reductions in systolic blood pressure following exercise in hypertensive individuals. ATP is a well-established signaling molecule in cardiac function, acting via purinergic receptors to regulate heart rate and vascular tone. The 2021 systematic review by Freitas et al. identifies cardiovascular health as a primary domain of benefit from oral ATP disodium.

Biomedical research documents bamboo-derived products' protective effects against cardiovascular disease markers, including cholesterol reduction, blood pressure lowering, and anti-inflammatory activity. TCM uses bamboo leaf extracts to promote cardiovascular health. Bamboo extract reduces MCP-1, a chemokine associated with atherosclerosis, and improves lipid profiles in animal models.

Corosolic acid from banaba has demonstrated antihyperlipidemic, antihypertensive, and antioxidant effects relevant to cardiovascular risk in animal models. A human RCT in metabolic syndrome patients showed banaba significantly reduced systolic blood pressure. Banaba has also been incorporated into human nutraceutical trials targeting cardiovascular risk factors including cholesterol and inflammation.

Bananas support heart health primarily through potassium, dietary fiber, and antioxidant polyphenols. Potassium intake from sources like bananas is associated with reduced stroke risk and cardiovascular events in large cohort studies. Banana fiber reduces LDL cholesterol and cardiovascular risk, and banana polyphenols exhibit anti-atherosclerotic properties.

Baobab's cardiovascular relevance is supported by multiple mechanisms: its high soluble fiber reduces LDL-cholesterol; its polyphenols inhibit HMG-CoA reductase and pancreatic lipase in silico; its antioxidant content may limit LDL oxidation and endothelial damage; and its glycemic-lowering effect reduces cardiovascular risk from postprandial hyperglycemia. A registered RCT is currently assessing baobab's effects on multiple cardiometabolic risk markers including blood lipid profiles in humans with obesity.

Barberry and its alkaloid berberine have demonstrated cardioprotective effects in both human and experimental studies, including reduction of cardiovascular risk factors (cholesterol, triglycerides, blood pressure, blood sugar) and direct cardiac actions. Berbamine, another barberry alkaloid, protects against ischemia-reperfusion injury.

Barley's soluble fiber reduces LDL cholesterol, non-HDL cholesterol, and apolipoprotein B — all established cardiovascular risk factors. The FDA recognizes a heart disease risk-reduction claim for barley soluble fiber at ≥0.75 g/serving. Multiple RCTs and meta-analyses underpin this evidence.

Icariin exerts cardioprotective effects in animal models of heart failure and ischemia by suppressing NF-κB/caspase-3 signaling, elevating cGMP and Nrf2, and normalizing hemodynamics. Epimedium has demonstrated cardiovascular benefits including improved vascular reactivity and endothelial function in human subjects. TCM tradition includes its use for coronary heart disease.

Basil constituents—particularly eugenol—have demonstrated calcium channel-blocking activity that may lower blood pressure. Clinical evidence from the 2017 systematic review of 24 trials found improvements in blood pressure and lipid profiles. Animal studies show significant reductions in total cholesterol and triglycerides. Cardioprotective effects have been reported in rat models.

Bee pollen has documented anti-atherosclerotic, antihypertensive, and lipid-lowering properties in animal and preliminary human evidence. A PMC review notes it can improve microcirculation and dyslipidemia and may prevent coronary heart disease. Fermented bee pollen postbiotics modulated cardiovascular microbiota in vitro.

Beetroot juice consistently lowers systolic blood pressure via dietary nitrate conversion to nitric oxide, improving endothelial function. Multiple meta-analyses of RCTs confirm reductions of ~3–5 mmHg in systolic BP. Betanin also attenuates LDL oxidation and atherogenic processes. Evidence is strongest for short-term and moderate-intensity hypertension.

Animal studies show T. bellirica extract protects against drug-induced cardiotoxicity, reduces CK-MB levels, restores cardiac antioxidant status, and improves lipid profiles (reducing cholesterol and triglycerides while increasing HDL). In vitro evidence demonstrates inhibition of LDL oxidation and macrophage-driven atherogenic inflammation. Traditional Ayurvedic use in Triphala includes prevention of heart tissue death. Human clinical evidence is lacking.

In preclinical models, benfotiamine reduced myocardial infarct size, normalized cardiac enzyme elevations, and improved post-ischemic functional recovery by inhibiting NADPH oxidase and NF-κB signaling. A rat MI model showed pre- and post-treatment with benfotiamine significantly decreased cardiac markers of oxidative stress, inflammation, and apoptosis. Human heart data is currently lacking.

Berberine, a plant alkaloid from Coptis chinensis and related herbs, has substantial clinical and trial-level evidence supporting multiple cardiovascular benefits, including lipid-lowering, antihypertensive, antiarrhythmic, and anti-atherosclerotic effects. Multiple systematic reviews and meta-analyses of RCTs confirm reductions in LDL-C, total cholesterol, triglycerides, and inflammatory markers relevant to cardiovascular disease. Evidence also supports benefits in heart failure and arrhythmia, though overall trial quality is variable and large, long-term RCTs remain limited.

Mixed tocopherols including beta and delta forms protect LDL from oxidative modification, inhibit smooth muscle cell proliferation, and reduce platelet aggregation—key mechanisms in cardiovascular disease. A human RCT showed mixed tocopherols (including delta-tocopherol) significantly reduced ADP-induced platelet aggregation, whereas alpha-tocopherol alone did not. Observational data link higher plasma levels of non-alpha tocopherols with lower cardiovascular disease incidence.

Beta-glucan, a soluble fiber primarily from oats and barley, has robust clinical evidence supporting its role in reducing LDL and total cholesterol—a key cardiovascular risk factor. Multiple meta-analyses of randomized controlled trials consistently show significant LDL reductions at doses of ≥3 g/day. Both the U.S. FDA and the European Food Safety Authority (EFSA) have authorized formal heart health claims for oat and barley beta-glucan based on this evidence. The primary mechanism involves beta-glucan forming a viscous gel in the gut that binds bile acids, increasing their fecal excretion and compelling the liver to draw more circulating cholesterol for new bile acid synthesis.

Beta-sitosterol, the predominant dietary phytosterol, has well-documented clinical evidence for lowering LDL cholesterol—a major cardiovascular risk factor—by competing with cholesterol for intestinal absorption. Multiple randomized controlled trials and meta-analyses confirm LDL reductions of roughly 8–15% at doses of 2 g/day or more, without adversely affecting HDL cholesterol. The U.S. FDA authorizes an official health claim linking plant sterol ester consumption (of which beta-sitosterol is the primary component) to reduced coronary heart disease risk. Long-term hard cardiovascular endpoint data (e.g., reduction in actual CHD events) remains limited.

Betaine (trimethylglycine) has well-documented clinical evidence for lowering plasma homocysteine, an established cardiovascular risk marker, via remethylation of homocysteine to methionine. Multiple randomized controlled trials and meta-analyses confirm this homocysteine-lowering effect, though betaine supplementation at higher doses also raises LDL and total cholesterol, which partially offsets the cardiovascular benefit. The overall net effect on hard cardiovascular outcomes (myocardial infarction, stroke) has not been directly established in large intervention trials.

Clinical trials show bilberry supplementation improves exercise capacity, reduces oxidized LDL, and beneficially modulates cardiovascular risk factors including HDL cholesterol and endothelial function. An open-label RCT post-myocardial infarction found significant improvements in 6-minute walk test distance and oxidized LDL. Larger confirmatory trials are ongoing.

Meta-analyses of RCTs confirm N. sativa significantly reduces blood pressure, LDL-cholesterol, total cholesterol, triglycerides, and inflammatory markers relevant to cardiovascular risk. A 2025 meta-analysis of 82 RCTs comprehensively confirmed improvements across cardiovascular risk factors including blood pressure, lipid profile, and inflammatory biomarkers.

Black pepper and piperine favorably modulate multiple cardiovascular risk factors including LDL cholesterol, triglycerides, CRP, and blood pressure. An RCT in stroke patients found 12-week curcumin-piperine supplementation reduced carotid intima-media thickness and systolic/diastolic blood pressure alongside lipid improvements.

Epidemiological studies and clinical trials collectively support a role for black tea in reducing major cardiovascular risk factors including LDL cholesterol, blood pressure, and endothelial dysfunction. The Cochrane review (2013) found statistically significant LDL reductions and BP reductions with black tea. Absolute effect sizes are modest.

Black walnut consumption is linked to cardiovascular benefits through its omega-3 fatty acids (ALA), phytosterols, and polyphenols. Human studies on walnut consumption show reductions in total cholesterol, LDL cholesterol, and improvements in endothelial function. A 2023 review found correlations between nut consumption and reduced cardiac events.

Blackberry polyphenols, particularly anthocyanins, are associated with cardioprotective effects through antioxidant, anti-inflammatory, and lipid-modulating mechanisms. A large meta-analysis of RCTs on anthocyanin-rich berries found significant reductions in total cholesterol and CRP. Vitamin C and fiber in blackberries also contribute to cardiovascular risk reduction as documented in epidemiological literature.

Fucoidan in bladderwrack exhibits antithrombotic and anticoagulant activity in platelet models, and the Gdue combination clinical study found reductions in blood pressure, LDL, and triglycerides. Epidemiological data show that regular seaweed consumers have ~12% lower ischemic heart disease risk.

Epidemiological and clinical evidence links regular anthocyanin-rich blueberry intake with reduced cardiovascular disease risk factors, including improvements in lipids and endothelial function. RCT data on individual CVD biomarkers are mixed but directionally favorable in at-risk populations.

GLA from borage oil metabolizes to DGLA, which has anti-thrombotic, vasodilatory, and lipid-modulating effects relevant to cardiovascular health. Long-term supplementation studies in RA patients showed beneficial cardiovascular effects including improved lipid profiles and blood pressure. ConsumerLab recognizes borage oil as a cardiovascular risk-modifying supplement when replacing saturated fats.

Bovine heart is the richest natural dietary source of CoQ10 (~11–13 mg/100 g), a coenzyme essential for cardiac energy metabolism. Clinical evidence for isolated CoQ10 at pharmacological doses (100–300 mg/day) shows improvements in heart failure outcomes, ejection fraction, and reductions in major cardiovascular events (Q-SYMBIO trial). Bovine heart also supplies taurine and L-carnitine, both of which have independent cardiovascular evidence. No RCTs exist specifically for bovine heart capsules; evidence is constituent-based.

Bovine liver's B12, folate, B6, and choline work through homocysteine reduction and methylation support — pathways relevant to cardiovascular disease risk. CoQ10 from liver has clinical evidence supporting heart function. Heme iron supports oxygen delivery to cardiac muscle. However, liver's high content of preformed vitamin A and cholesterol warrants moderation.

Boxthorn improves multiple cardiovascular risk factors including lipids, oxidative stress, and inflammation. A 16-week RCT in middle-aged adults consuming 15 g/day wolfberry showed plasma lipidomic alterations linked to cardiovascular protective outcomes. LBPs reduce proinflammatory cytokines and oxidative stress in heart failure animal models. Traditional Chinese medicine used boxthorn against arteriosclerosis and hypertension.

Brassicasterol is a phytosterol whose class has well-documented LDL-cholesterol-lowering effects in human clinical studies. Phytosterol intake of ≥2 g/day is endorsed by EFSA and the European Atherosclerosis Society as a cholesterol-lowering strategy. By reducing LDL-C, phytosterols including brassicasterol are positioned as adjunctive tools for cardiovascular risk reduction, though direct randomized endpoint trials for brassicasterol alone are lacking.

Observational data link higher cruciferous vegetable intake to reduced cardiovascular mortality. A meta-analysis of 10 clinical trials found that broccoli sprout supplementation significantly reduced systolic and diastolic blood pressure. Sulforaphane protects vascular endothelium via Nrf2 activation, reducing oxidative stress and atherosclerotic signaling.

Brown rice and its protein contain compounds (subaleurone-layer peptides, γ-oryzanol, ferulic acid) that inhibit angiotensin II — a key driver of hypertension and atherosclerosis — as reported by Temple University researchers. A 3-month human dietary intervention study (n=56 hyperlipidemic patients) showed germinated brown rice significantly reduced total cholesterol, LDL-C, triglycerides, and ApoB while increasing HDL-C. Meta-analyses also link whole-grain brown rice to reduced CVD risk factors.

Brussels sprouts contribute to cardiovascular health through multiple nutrients: soluble fiber lowers LDL cholesterol, potassium supports blood pressure regulation, folate reduces homocysteine, and glucosinolates/omega-3 ALA exert anti-inflammatory vascular effects. Higher cruciferous vegetable intake is epidemiologically associated with reduced cardiovascular disease risk.

Cabbage provides anthocyanins (red cabbage), phytosterols, fiber, potassium, and vitamin C—all with documented cardiovascular benefits. Higher cruciferous vegetable intake is associated with lower CVD risk in prospective cohort meta-analyses. Anthocyanin intake is associated with lower central blood pressure and reduced arterial stiffness in human studies.

Caffeine has complex, dose-dependent, and genotype-modulated effects on heart health. Acute intake transiently raises blood pressure and heart rate; habitual moderate consumption is generally not associated with increased cardiovascular disease risk in most epidemiological studies. Caffeine blocks adenosine receptors in coronary arteries, reducing adenosine-mediated vasodilation and potentially impairing myocardial blood flow response to exercise in at-risk individuals.

Calamari oil's DHA and EPA content supports heart health through multiple mechanisms including triglyceride reduction, modest heart rate lowering, and anti-inflammatory effects. The FDA has recognized supportive but not conclusive evidence that EPA and DHA may reduce coronary heart disease risk. A meta-analysis of 51 RCTs found omega-3 supplementation significantly reduced resting heart rate.

Campesterol, as a representative phytosterol, is clinically linked to heart health primarily through its role in reducing LDL cholesterol. The KEEP cohort study found higher baseline campesterol levels were significantly associated with fewer cardiovascular events in elderly hypercholesterolemic patients. Meta-analyses of RCTs confirm that phytosterol mixtures containing campesterol reduce LDL-C by 6–12% at ~2 g/day. Study results on serum campesterol as a direct cardiac risk marker remain conflicting.

Camu camu's anthocyanins and polyphenols have been associated with reduced oxidative stress and inflammatory markers relevant to atherosclerosis in human subjects. A human crossover study documented vasodilation and blood pressure reduction after a single oral dose of camu camu pericarp extract. Systematic review notes the presence of anthocyanins, investigated in clinical trials for blood pressure and endothelial function.

Population studies associate habitual spicy food consumption with reduced cardiovascular mortality. TRPV1 activation by capsaicin has been shown to improve endothelial function and vascular health in experimental models. Evidence also points to cardioprotective effects through blood pressure modulation and lipid metabolism.

Capsanthin has demonstrated cardioprotective effects in preclinical models through its anti-inflammatory, lipid-lowering, and anti-atherosclerotic actions. Raising HDL-C and reducing LDL-C, triglycerides, and vascular inflammation are documented mechanisms. An exploratory human study showed significant HDL-C increase after paprika/capsanthin supplementation.

Capsaicin has demonstrated cardioprotective properties including lipid-lowering, mild antihypertensive, antiplatelet, and anti-ischemic effects in clinical and epidemiological studies. A 2026 systematic review and meta-analysis of RCTs confirmed modest reductions in total cholesterol and diastolic blood pressure with capsaicin supplementation.

Cardamom has documented favorable effects on multiple cardiovascular risk markers in clinical trials, including reductions in blood pressure, triglycerides, total cholesterol, and inflammatory markers (hs-CRP, IL-6). A 2024 meta-analysis (12 RCTs, n=989) concluded cardamom improves specific cardiovascular metabolic biomarkers. Animal data additionally suggest antiplatelet and antithrombotic properties.

Observational studies showed early promise for beta-carotene in cardiovascular protection, but multiple RCTs including the ATBC, CARET, and Physicians' Health Study demonstrated no benefit—and potential harm in at-risk populations. A systematic review and meta-analysis found beta-carotene supplementation had no beneficial effects on CVD incidence and potential harmful effects on CVD mortality. Current evidence does not support beta-carotene supplementation for heart health.

Epidemiological studies link higher carotenoid blood levels from carrot-rich diets with lower atherosclerotic burden and reduced cardiovascular disease risk. Animal models show carrot supplementation reduces blood pressure and aortic atherosclerotic lesions. Human pilot data show modest systolic blood pressure reduction with daily carrot juice.

Cinnamon bark, primarily from C. cassia, has been reviewed for cardiovascular protective effects including reductions in LDL cholesterol, triglycerides, and CRP. Reviewed literature indicates cinnamon can reduce the risk of cardiac ischemia, hypertrophy, and myocardial infarction in preclinical models, with some supportive human data on lipid and glucose parameters relevant to cardiovascular risk.

Catechins, polyphenolic compounds concentrated in green tea, cocoa, and other plants, have substantial human clinical evidence supporting cardiovascular benefits. Multiple meta-analyses of randomized controlled trials demonstrate reductions in blood pressure, LDL cholesterol, and improvements in endothelial function. The evidence is strongest for blood pressure reduction and lipid lowering, though effect sizes are modest and long-term clinical significance remains under investigation.

Cowpea's LDL- and triglyceride-lowering effects, antihypertensive peptides, and antioxidant polyphenols collectively support cardiovascular health. There is growing evidence it is a functional food able to reduce hypercholesterolemia, a major cause of cardiovascular disease. Both human and animal studies support this link.

Epidemiological studies link higher cruciferous vegetable consumption, including cauliflower, to lower cardiovascular disease risk. Sulforaphane reduces oxidative stress in arterial walls via Nrf2 activation, while dietary fiber in cauliflower contributes to bile acid binding and cholesterol lowering. Both mechanisms are supported by human data.

Observational data show regular chili pepper consumption is associated with a 13% reduction in all-cause mortality and lower risk of heart attack and stroke. Capsaicin has demonstrated effects on cholesterol, blood pressure, fibrinolytic activity, and vascular inflammation, though RCT evidence for hard cardiovascular endpoints is limited.

Multiple RCTs and a 2025 meta-analysis confirm celery preparations significantly reduce systolic and diastolic blood pressure, and lower triglycerides—key cardiovascular risk markers. Phthalides in celery relax vascular smooth muscle and block calcium channels. Evidence is robust for BP reduction.

A. aspera shows cardiovascular activity in preclinical models including blood pressure lowering, cardiac stimulation via water-soluble alkaloids, and phosphorylase activity of saponins on cardiac tissue. Traditional use also cites it for hypertension.

Chen Pi flavonoids (hesperidin, nobiletin, tangeretin) protect cardiovascular function by improving endothelial function, inhibiting macrophage foam-cell formation, reducing lipid oxidation, and lowering atherogenic lipids. Clinical data come from hesperidin RCTs and lipid-lowering trials.

Tart cherry has been studied for several cardiovascular risk factors in human RCTs, with evidence for modest reductions in systolic blood pressure, LDL cholesterol, and CRP in older adults. Meta-analyses show inconsistent pooled effects, and no large trials have used hard cardiovascular endpoints.

Multiple meta-analyses of RCTs demonstrate chia supplementation significantly reduces systolic blood pressure, total cholesterol, LDL-C, and triglycerides — all established cardiovascular risk factors. ALA omega-3s, fiber, and antioxidants all contribute mechanistically to cardiovascular protection.

Multiple clinical trials and a systematic review document that chickpea consumption reduces total cholesterol, LDL-C, and high-sensitivity CRP—key cardiovascular risk factors. A 12-week RCT in people with prediabetes showed total cholesterol fell from 200.4 to 185.8 mg/dL and LDL-C from 131.9 to 119.3 mg/dL in the chickpea group. ACE-inhibitory peptides derived from chickpea protein may additionally lower blood pressure.

Chicory inulin and root extracts have demonstrated effects on cardiovascular risk markers in clinical studies, including reductions in total cholesterol, LDL, triglycerides, and blood pressure in hypertensive individuals. Evidence is clinically meaningful primarily in dyslipidemias and metabolic disease contexts.

Danshen has been the subject of 39+ clinical trials for cardiovascular disease including heart failure, coronary heart disease, and myocardial ischemia. Its active compounds protect cardiomyocytes against ischemia-reperfusion injury and cardiac fibrosis. Compound Danshen Dripping Pills were the first TCM product to enter FDA Phase II clinical trials for cardiovascular disease.

Meta-analyses of RCTs show chlorella supplementation improves multiple cardiovascular risk factors including total cholesterol, LDL-C, blood pressure, and insulin sensitivity. Evidence is graded as high quality for TC and LDL-C reductions. Some newer meta-analyses using different inclusion criteria show neutral effects on BP and lipemia, indicating overall results are not fully consistent.

Chokeberry improves multiple cardiovascular risk factors in human clinical trials, including blood pressure, lipid profiles, and coagulation markers. Combination therapy with statins plus chokeberry extract was shown to enhance reduction of cardiovascular risk markers in post-myocardial infarction patients. The evidence base is primarily in at-risk populations including metabolic syndrome and post-MI patients.

The relationship between choline and heart health is scientifically documented but notably dual-directional and contested. Adequate dietary choline intake has been associated with lower CVD and stroke risk in large observational studies, while elevated circulating choline is also a precursor to TMAO, a gut-microbiota-derived metabolite independently linked to higher cardiovascular event risk. Preclinical studies show choline can reduce cardiac hypertrophy and hypertension-related damage via anti-inflammatory and vagal-activity mechanisms. Overall, the evidence is complex: dietary choline adequacy may be cardioprotective, while excess choline—particularly via the TMAO pathway—may be pro-atherogenic.

Chrysin demonstrates cardioprotective effects in preclinical models via antioxidant, anti-inflammatory, and hypolipidemic mechanisms. It has shown protection against myocardial ischemia-reperfusion injury, reduced dyslipidemia, and inhibited atherosclerotic processes including vascular inflammation and platelet activation. No human cardiovascular clinical trials have been conducted.

Cinnamon supplementation significantly reduces total cholesterol, triglycerides, LDL-C, systolic and diastolic blood pressure, and CRP across multiple RCTs and meta-analyses—collectively addressing major cardiovascular risk factors. A 2025 GRADE meta-analysis of 49 RCTs confirmed improvements across blood pressure, lipids, and glycemic markers.

Citrus pectin exerts cardiovascular benefits primarily via LDL-cholesterol reduction and, in modified form (MCP), via inhibition of galectin-3, a driver of cardiac fibrosis. Human trials show significant LDL lowering; preclinical data link MCP to reduced cardiac fibrosis and media thickening in hypertension models. The FDA recognizes soluble fiber's role in reducing heart disease risk.

C. sinensis flavanones improve endothelial function, reduce vascular adhesion molecules, and favorably affect lipid and glucose biomarkers relevant to cardiovascular risk. A meta-analysis of 12 RCTs confirmed hesperidin reduces LDL, total cholesterol, CRP, ICAM-1, and VCAM-1. Multiple RCTs document blood pressure reductions.

CLA has been investigated as a cardiovascular risk modifier. Meta-analyses show it reduces body fat and BMI in at-risk populations but has no significant effect on blood pressure or lipid profile in CVD-risk patients. A prospective cohort study linked higher serum CLA to significantly reduced risk of incident heart failure.

The large-scale COSMOS RCT (N=21,442, 3.6 years) found that cocoa extract supplementation reduced cardiovascular disease mortality by 27%. Cocoa flavanols also improve cardiac remodeling markers and endothelial function. Multiple smaller RCTs and meta-analyses support broad cardiometabolic benefits.

Clinical trial data and meta-analyses consistently show coconut oil raises both LDL-C and HDL-C relative to unsaturated vegetable oils. Mainstream cardiovascular bodies including the American Heart Association do not support coconut oil as heart-healthy due to LDL-raising effects. Epidemiological data from traditional coconut-consuming populations are confounded by overall diet patterns.

Clinical evidence on coconut milk and cardiovascular outcomes is primarily indirect, operating through lipid biomarkers. Coconut milk's MCFAs raise HDL and may promote reverse cholesterol transport, but epidemiological data also show frequent coconut milk intake (>3x/week) was associated with a 1.3-fold increased vascular disease risk. The evidence is genuinely mixed and no long-term cardiovascular endpoint trials exist specifically for coconut milk.

Cod liver oil contributes to cardiovascular health primarily through triglyceride reduction, modest HDL elevation, and anti-inflammatory and antithrombotic effects. A large interventional study (870 patients) found fewer myocardial infarction events with CLO supplementation. Evidence for broad cardiovascular event reduction is more mixed.

Coenzyme A (CoA) is an essential cofactor for cardiac energy metabolism, participating in over 100 metabolic reactions including fatty acid oxidation and the TCA cycle. Accumulating evidence identifies impaired CoA homeostasis as a pathomechanism in cardiac dysfunction and certain cardiomyopathies. Direct human evidence of CoA deficiency in cardiac disease emerged first in 2018, and recent research explores restoring CoA levels — via vitamin B5 and its derivatives — as a strategy to support heart function in affected patients.

Polyphenol extracts of coix have demonstrated cardioprotective effects via reducing serum total cholesterol, LDL-C, and increasing HDL-C in animal models. Coix inhibits liver cholesterol synthesis and has anti-hypertensive properties noted in pharmacological reviews.

Forskolin has demonstrated positive inotropic effects in human myocardial tissue preparations and early clinical trials with intravenous administration in heart failure patients. It activates adenylate cyclase in myocardial cells independently of beta-adrenergic receptors, increasing cardiac contractile force. Evidence for oral supplementation in heart health is not established.

Studies indicate that diets incorporating collard greens reduce systolic blood pressure and improve lipid profiles. Their soluble fiber binds bile acids to lower LDL cholesterol, while potassium and folate support vascular function. A study in spontaneously hypertensive rats showed that collard greens decreased systolic blood pressure and LDL cholesterol; epidemiological evidence links green leafy vegetable intake to a ~16% reduction in cardiovascular disease risk.

Copper deficiency impairs cardiac structure and function through reduced collagen/elastin cross-linking, diminished mitochondrial respiration, and impaired angiogenesis in myocardial tissue. Epidemiological cohort studies link dietary copper intake to myocardial infarction risk. Animal models demonstrate that copper supplementation reverses copper-deficiency-induced cardiac dysfunction.

Berberine from Coptis chinensis shows cardioprotective properties including anti-arrhythmic, anti-atherosclerotic, antihypertensive, and lipid-lowering effects supported by pharmacological and clinical studies. Multiple studies and reviews document cardiovascular benefits spanning lipid regulation, plaque stabilization, and AMPK activation.

CoQ10 has substantial clinical evidence supporting its role in heart health, particularly in heart failure (HF). As an essential cofactor for mitochondrial ATP production and a potent antioxidant, CoQ10 levels are measurably depleted in HF patients and correlate inversely with disease severity. The landmark Q-SYMBIO randomized controlled trial demonstrated significant reductions in cardiovascular mortality and major adverse cardiac events with supplementation. Evidence also supports benefits in endothelial function, vascular stiffness, and oxidative stress across broader cardiovascular disease contexts.

Cordyceps has demonstrated clinical benefits for cardiac arrhythmia in a 2022 meta-analysis of 19 RCTs involving 1,805 patients, improving outcomes in both bradycardia and tachycardia. Animal and early human studies suggest cardioprotective effects through antioxidant, anti-inflammatory, and anti-atherosclerotic mechanisms. Cordycepin has been identified in preclinical work as a potential agent against cardiac hypertrophy.

Corn silk has human clinical trial evidence for blood pressure reduction and lipid improvement in cardiovascular patients, including those with angina. Its antioxidant and anti-inflammatory properties support overall cardiovascular health in preclinical models. Blood pressure meta-analysis (5 RCTs, n=567) and lipid meta-analysis (4 RCTs) provide the strongest clinical evidence.

CSO's PUFA-rich profile and its demonstrated effects on cholesterol, triglycerides, and inflammatory markers suggest a cardioprotective dietary role. The 12.2% LDL-C reduction observed in an 8-week RCT is estimated to correspond to a 14.6–21.4% reduction in coronary artery disease risk. Ongoing research continues to evaluate CSO as a nutritional approach for improving cardiometabolic risk.

Multiple RCTs demonstrate that cranberry consumption improves endothelial function (flow-mediated dilation), reduces arterial stiffness, and modestly lowers CRP and triglycerides. A double-blind RCT in 45 healthy men showed a 1.1% improvement in FMD persisting at one month. Evidence on lipid profiles (LDL, HDL, total cholesterol) is mixed across studies.

The heart relies heavily on the phosphocreatine/creatine kinase system for sustained ATP production. Cardiac creatine depletion is a documented hallmark of heart failure and correlates with reduced ejection fraction and mortality. Preliminary clinical trials suggest creatine may support skeletal muscle performance and vascular health in cardiac patients, though large-scale RCTs remain lacking.

Creatine is a key component of cardiac energy metabolism, with the phosphocreatine-creatine kinase system playing a critical role in cardiomyocyte energy buffering. Clinical evidence supports potential benefits for vascular health and emerging investigational uses in heart failure and cardioprotection during chemotherapy.

Observational data link higher BCX intake to reduced cardiovascular disease risk, oxidized LDL, and arterial inflammation. BCX suppresses NF-κB-driven endothelial inflammation and improves cardiometabolic markers in animal models. Serum carotenoid studies in metabolic syndrome populations support an inverse relationship with cardiovascular mortality.

Cucumber provides potassium, magnesium, and plant sterols that collectively support cardiovascular function via blood pressure reduction, vasodilation, and LDL lowering. Animal and limited human evidence supports lipid-lowering and anti-hypertensive effects. The Mediterranean-diet review also recognises cucumber as a heart-supportive food.

Cumin favorably affects several cardiovascular risk factors including total cholesterol, LDL, HDL, and triglycerides across multiple RCTs and meta-analyses. Its antioxidant compounds protect arterial walls from oxidative damage. Overall cardiovascular endpoint data in humans are lacking, but intermediate biomarker data are supported by clinical trials.

Curcumin has been investigated in multiple randomized controlled trials and systematic reviews for cardiovascular benefits, including improvements in endothelial function, lipid profiles, and inflammatory markers. Key mechanisms involve inhibition of NF-κB signaling, reduction of oxidative stress, and increased nitric oxide bioavailability. Evidence is promising but constrained by curcumin's poor oral bioavailability and the need for larger, longer-duration trials.

Multiple human RCTs and a large meta-analysis support blackcurrant anthocyanins improving cardiovascular risk factors including vascular function, lipid profiles, platelet aggregation, and inflammatory markers. Prospective cohort data link high anthocyanin diets to lower CHD risk.

D-alpha tocopherol inhibits LDL oxidation, reduces platelet aggregation, and has anti-inflammatory actions in the vasculature, providing a plausible cardioprotective mechanism. However, large RCTs including HOPE, GISSI, and pooled analyses have not demonstrated a significant reduction in cardiovascular events with supplementation, making the clinical benefit for established heart disease uncertain.

Multiple clinical trials demonstrate that D-ribose supplementation improves cardiac energy metabolism, diastolic function, and exercise tolerance in patients with coronary artery disease and congestive heart failure. The mechanism centers on D-ribose accelerating myocardial ATP repletion following ischemia. Evidence includes a double-blind randomized crossover trial and a dobutamine stress echocardiography study.

In vitro and animal models demonstrate daidzin and daidzein reduce markers of myocardial infarction, hyperlipidemia, thrombosis, hypertension, and oxidative stress relevant to cardiac health. A 2024 systematic review confirmed these preclinical findings, while clinical data confirm only modest anti-hyperlipidemic effects.

Animal models show dandelion polysaccharides inhibit atherosclerosis development via antioxidant and anti-inflammatory mechanisms. Dandelion also demonstrates hypolipidemic activity in cholesterol-fed animal models, with reduced aortic lesion formation. Clinical human cardiovascular outcome data are absent, but the preclinical mechanistic picture is consistent.

Mixed tocopherols including delta-tocopherol inhibit smooth muscle cell proliferation, reduce LDL oxidation, and show anti-inflammatory effects in vascular tissue relevant to heart disease. All tocopherols except β-tocopherol inhibit smooth muscle proliferation, a key atherogenic process. Epidemiological studies have suggested cardioprotective effects of vitamin E, though large RCTs using α-tocopherol alone have been negative, and δ-tocopherol-specific cardiac RCTs have not been conducted.

DHA (docosahexaenoic acid), a marine-derived omega-3 fatty acid, has robust clinical and epidemiological evidence supporting its role in cardiovascular health. It lowers triglycerides, reduces blood pressure, improves vascular function, and is associated with reduced risk of cardiovascular events and mortality. Evidence from meta-analyses of randomized controlled trials and cohort studies consistently links higher DHA intake or circulating levels to improved cardiac outcomes, though DHA's independent effect versus EPA remains an area of active investigation.

Dioscorea constituents, particularly dioscin and diosgenin, have shown cardioprotective effects in animal models via lipid-lowering, anti-atherosclerotic, anti-inflammatory, and estrogen receptor-mediated pathways. Dioscin has been found to attenuate postmenopausal atherosclerosis in animal models. Human evidence is limited.

Extensive epidemiological and interventional evidence supports DHA's cardioprotective effects, principally through triglyceride reduction, HDL improvement, blood pressure and heart rate lowering, and platelet function modulation. The landmark GISSI-Prevenzione trial showed significant reduction in cardiovascular death with EPA+DHA supplementation post-MI. DHA specifically demonstrates a somewhat greater triglyceride-lowering and heart-rate-lowering effect than EPA.

Rosehip has demonstrated cardiovascular benefits in human clinical trials, including reductions in systolic blood pressure and LDL cholesterol. A crossover RCT in obese subjects found a 3.5% reduction in systolic blood pressure and a 6% decrease in LDL cholesterol after 6 weeks of rosehip beverage. A systematic review of 4 RCTs confirmed reductions in LDL, blood pressure, and cardiovascular risk scores.

Pharmacological research demonstrates that A. sinensis and its constituents protect cardiac myocytes, reduce myocardial injury, inhibit platelet aggregation, and exhibit antiarrhythmic effects. Ferulic acid has shown clinical utility in coronary atherosclerotic disease in Chinese trials. Both in vitro and in vivo studies support cardioprotective actions, though large Western RCTs are absent.

Higher plasma DPA concentrations are associated with lower risk of myocardial infarction in large prospective studies. A pooled analysis of 19 cohort studies found each standard deviation increase in DPA was associated with approximately 9% lower risk of fatal coronary heart disease. DPA also reduces inflammatory gene expression in arterial walls and inhibits platelet aggregation, addressing core mechanisms of cardiac risk.

Dulse contains potassium (a vasodilator mineral) and yields ACE-inhibitory peptides from its phycobiliproteins upon hydrolysis, both of which are relevant to cardiovascular health. Nine ACE-inhibitory peptides have been isolated from dulse hydrolysate, with peptide LRY showing notably high ACE inhibitory activity (IC50 0.044 µmol) in vitro. Dulse's omega-3 fatty acids and polyphenols may further contribute to cardiovascular protection via anti-inflammatory mechanisms.

EGCG (epigallocatechin gallate), the principal catechin in green tea, has clinical and meta-analytic evidence supporting cardiovascular benefits including LDL cholesterol reduction, blood pressure lowering, and improved endothelial function. A systematic review of 17 RCTs found that 107–856 mg/day for 4–14 weeks reduced LDL-C by approximately 9.3 mg/dL. A separate crossover trial in coronary artery disease patients showed acute endothelial function improvement following a single 300 mg dose. Evidence is promising but not yet conclusive across all populations.

Egg consumption and heart health is one of the most extensively studied and contested dietary relationships. Evidence is mixed: most prospective cohort meta-analyses find no significant cardiovascular risk increase at up to 1 egg/day in healthy adults, but a 2019 JAMA pooled analysis found higher dietary cholesterol from eggs was associated with increased CVD risk. Saturated fat context and overall dietary pattern appear critical modifiers.

EPA is one of the most extensively studied nutrients for cardiovascular outcomes. The REDUCE-IT trial demonstrated a 25% reduction in major adverse cardiovascular events with high-dose prescription EPA (icosapent ethyl, 4 g/day) in statin-treated patients. EPA modulates lipids, reduces platelet aggregation, stabilizes plaques, and improves endothelial function.

Eicosenoic acid-rich marine oil diets have been shown in animal models to reduce risk factors for cardiovascular disease and atherosclerosis. Long-chain MUFA (LCMUFA) fractions, of which eicosenoic acid is a prominent constituent in fish oils such as saury and pollock oil, also suppressed lipid deposition in vessel walls and improved plasma lipid profiles in rodent studies. No isolated human clinical trials on eicosenoic acid for heart health exist; evidence is preclinical.

EPA (eicosapentaenoic acid) has robust clinical evidence supporting its role in cardiovascular risk reduction, particularly at high doses in statin-treated patients with elevated triglycerides. Landmark randomized controlled trials — REDUCE-IT and JELIS — demonstrated significant reductions in major adverse cardiovascular events (MACE). EPA works through multiple mechanisms including triglyceride lowering, anti-inflammatory, antiplatelet, and plaque-stabilizing effects. High-dose EPA is FDA-approved and carries a Class IIa recommendation from the European Society of Cardiology for high-risk patients.

Eucommia's antihypertensive, lipid-lowering, anti-inflammatory, and antioxidant effects collectively benefit cardiac health. Preclinical studies show it reduces cardiac workload by lowering peripheral resistance and improving vascular tone. Human clinical evidence for direct cardiac endpoints is limited but indirectly supported via BP and lipid trials.

EPO's GLA content has been studied in the context of cardiovascular risk factors including cholesterol, triglycerides, and platelet aggregation. Clinical evidence is limited and indirect—effects on lipid profiles have been demonstrated in adjunct studies, but dedicated cardiovascular endpoint trials are lacking. The lipid-modulating effects represent the primary mechanistic link.

Fava beans are rich in soluble fiber, potassium, magnesium, folate, and polyphenols—all nutrients associated with cardiovascular risk reduction. Clinical and epidemiological evidence links regular legume consumption to lower LDL cholesterol, reduced CHD risk, and improved cardiovascular biomarkers.

Multiple in vitro and animal studies document antihypertensive, vasorelaxant, hypolipidemic, antiplatelet, and antioxidant cardiovascular effects for Foeniculum vulgare. A 2025 comprehensive review (PMC) systematized this evidence. Human clinical data remain limited.

Multiple systematic reviews and meta-analyses of RCTs show fenugreek supplementation significantly reduces total cholesterol, LDL-C, and triglycerides, while raising HDL-C, in subjects with metabolic syndrome and type 2 diabetes. These lipid-modulating effects reduce cardiovascular risk factors. Additional antioxidant and anti-inflammatory properties provide further cardioprotective benefit.

Ferulic acid exerts cardioprotective effects by improving lipid profiles, reducing oxidative stress and inflammation, lowering blood pressure, and inhibiting platelet aggregation. Human RCT data show significant improvements in all major cardiovascular risk biomarkers with 1 g/day FA. Sodium ferulate has been used in traditional Chinese medicine for cardiovascular and cerebrovascular disease.

Fisetin protects against high-fat-diet-induced cardiac dysfunction, diabetic cardiomyopathy, and metabolic-stress cardiac injury in rodent models through anti-inflammatory, antioxidant, and anti-fibrotic mechanisms. No human cardiac trials exist.

Fish oil omega-3s are one of the most extensively studied dietary supplements for cardiovascular health. Their most robust and FDA-recognized effect is triglyceride reduction (dose-dependent, up to 30–45% at high doses). Large RCTs including REDUCE-IT (icosapentaenoic acid) demonstrate significant reductions in major adverse cardiovascular events (MACE) in high-risk populations. Effects on reducing overall CVD mortality have been inconsistent across trials.

Flaxseed has substantial clinical and human trial evidence supporting its role in cardiovascular health. Its three primary bioactive constituents—alpha-linolenic acid (ALA), the lignan secoisolariciresinol diglucoside (SDG), and soluble fiber—collectively contribute to reductions in LDL cholesterol, total cholesterol, and blood pressure. Multiple systematic reviews and meta-analyses of randomized controlled trials confirm these effects, though effect sizes are modest and results show heterogeneity across studies.

Folic acid is scientifically linked to cardiovascular health primarily through its role in lowering homocysteine, an amino acid associated with increased CVD risk. Multiple RCT meta-analyses confirm a modest but significant reduction in stroke risk (~10–15%) and a small reduction in overall CVD risk, though benefits for coronary heart disease and mortality are not established. The NIH ODS notes that while folic acid lowers homocysteine, it does not directly decrease the risk of heart disease itself. Benefits appear most pronounced in populations with low baseline folate levels and without preexisting CVD.

Forskolin is a positive inotrope that raises cAMP in cardiac muscle, increasing contractility. Two clinical trials using intravenous forskolin found positive cardiovascular effects in heart failure patients. A water-soluble derivative (colforsin daropate) is approved in Japan for acute heart failure.

Forsythiasides—the phenylethanol glycosides of Forsythia suspensa—have been shown in preclinical studies to exert cardiovascular protective effects, with forsythoside A demonstrating antioxidant and cardioprotective properties in experimental models. Forsythia is also traditionally used as a cardiovascular tonic. No large human clinical trials for heart health specifically have been published.

Gamma oryzanol supports heart health primarily through lipid lowering and vascular protective effects. It reduces adhesion molecule expression in vascular endothelium via NF-κB suppression, and animal data show it protects against structural and functional cardiac alterations induced by metabolic stress. It is approved in Japan for cardiovascular-related lipid management.

Epidemiological data show that plasma γT levels are inversely associated with coronary artery disease (CAD), and that CAD patients have lower γT but normal α-tocopherol. In animal models, γT outperforms α-tocopherol in inhibiting LDL oxidation, platelet aggregation, and arterial thrombus formation. Evidence from prospective human cohorts is mixed and inconsistent.

Ganoderma lucidum triterpenes inhibit ACE and platelet aggregation in vitro, and animal studies demonstrate cardioprotective effects. Human studies on cardiovascular risk factors show mixed results, with the best-designed RCT finding no significant effects on blood pressure, lipids, or glucose in metabolic syndrome patients.

Chickpeas support heart health through multiple simultaneous pathways: LDL reduction, triglyceride lowering, blood pressure moderation via potassium and magnesium, and anti-inflammatory polyphenol activity. Epidemiologic and interventional studies link regular pulse consumption, including chickpeas, to reduced cardiovascular disease risk. A 2024 review of 30 clinical and observational studies reported consistent evidence that pulse consumption supports positive cardiovascular outcomes.

Geniposide from Gardenia jasminoides has been shown to protect against myocardial dysfunction and ischemia-reperfusion injury in preclinical models, via anti-inflammatory, anti-apoptotic, and antioxidant mechanisms. A 2022 PMC review (Molecules) identified 'anti-myocardial dysfunction effect' among geniposide's confirmed pharmacological activities. Evidence is entirely preclinical.

Garlic has substantial clinical evidence supporting benefits across multiple cardiovascular risk factors, including blood pressure, lipid profiles, platelet aggregation, and oxidative stress. A 2025 meta-analysis of 108 RCTs (7,137 participants) found significant reductions in total cholesterol, LDL, triglycerides, and blood pressure. Effects are most pronounced in individuals with elevated baseline cardiovascular risk. Results are somewhat inconsistent across trials, partly due to variability in garlic preparations and dosing.

Garlic addresses multiple modifiable cardiovascular risk factors simultaneously: blood pressure, total cholesterol, platelet aggregation, and arterial stiffness. Multiple meta-analyses confirm modest but statistically significant effects on these surrogate markers. No large trial has yet demonstrated reduction in hard cardiovascular events.

Genistein has documented cardioprotective effects including improved cardiac function, protection against ischemia-reperfusion injury, reduced cardiac toxicity, and favorable modulation of lipid profiles. A 2023 review and multiple clinical meta-analyses confirm these findings. Effects are attributed to anti-inflammatory, antioxidant, and estrogenic mechanisms.

Multiple RCTs and systematic reviews support ginger's favorable effects on cardiovascular risk factors including triglycerides, LDL cholesterol, blood pressure, and inflammation. An umbrella review documented significant positive influence of ginger on inflammatory indices, blood pressure, blood lipid profile, and glycemic control. Ginger's anti-atherogenic effects are mediated via antioxidant, anti-inflammatory, and vasodilatory mechanisms.

Ginkgo biloba extract (GBE) has documented cardiovascular-relevant mechanisms — including vasorelaxation, inhibition of platelet aggregation, and improved coronary perfusion — supported by both laboratory and clinical data. However, the largest high-quality randomized trial (GEM Study, n=3,069) found no reduction in cardiovascular events or CVD mortality. Evidence is mixed overall, with clinical benefit most consistently demonstrated for peripheral arterial disease (intermittent claudication) rather than primary cardiac endpoints.

Ginseng (Panax ginseng) has documented clinical and preclinical evidence supporting cardiovascular benefits, primarily through its active compounds called ginsenosides. Human RCT meta-analyses show modest but statistically significant reductions in systolic blood pressure, LDL cholesterol, total cholesterol, and inflammatory markers (CRP, IL-6). Vascular function meta-analyses also show improved flow-mediated dilation and endothelial nitric oxide levels. Evidence strength is moderate; many individual trials are small and short-term, and not all endpoints reach significance across all reviews.

GLA has demonstrated several cardioprotective properties in human trials including reduction in triglycerides, LDL-cholesterol, platelet aggregation, thromboxane B2, and blood pressure, alongside increases in HDL-cholesterol and prostacyclin production. These lipid and platelet effects collectively reduce cardiovascular risk markers.

Glucomannan's documented reductions in LDL cholesterol, total cholesterol, triglycerides, and fasting blood glucose collectively address major cardiovascular risk factors. One controlled metabolic trial in T2DM patients also showed a 6.9% reduction in systolic blood pressure. These lipid and glycemic effects are considered indirectly cardioprotective.

Glycitein exhibits dual cardioprotective effects including blood pressure lowering via endothelial nitric oxide synthase (eNOS) activation and lipid profile improvement via PPAR-γ regulation. Clinical evidence at the isoflavone class level shows improved vascular compliance and favorable lipid changes in menopausal women. Cardiovascular disease is among the three primary clinical domains of glycitein noted in the 2025 ScienceDirect review.

LBP has demonstrated cardioprotective effects in animal models by reducing inflammatory cytokines and lipid peroxidation in heart failure, and human studies show favorable changes to lipid profiles (increased HDL, reduced LDL/TG) following goji supplementation. A randomized controlled trial in middle-aged and older adults confirmed improvements in cardiovascular lipid markers. The berry has been used in TCM for hypertension and atherosclerosis.

Amla demonstrates broad cardioprotective effects in clinical studies, including improvements in lipid profiles, blood pressure, endothelial function, and anti-platelet activity. A 2018 PMC systematic review of amla's cardiovascular pharmacology confirmed multiple evidence-based cardioprotective mechanisms.

Multiple RCTs and meta-analyses demonstrate grape seed extract's cardioprotective effects including reductions in blood pressure, oxidized LDL, and markers of vascular inflammation. A meta-analysis of 16 RCTs (810 subjects) found significant reductions in both SBP and DBP. GSE also reduces platelet aggregation, inhibits LDL oxidation, and improves endothelial function. Evidence supports a meaningful, multi-pathway benefit on cardiovascular risk factors.

GSE has been studied for multiple cardiovascular endpoints including blood pressure, LDL oxidation, endothelial function, and platelet aggregation. It reduces sICAM-1 and endothelin-1 in endothelial cells, inhibits platelet aggregation, and has been shown to improve endothelial function markers in diabetic patients. Traditional use of grapes for heart conditions dates to ancient Greece.

Multiple human studies have found that regular grapefruit consumption reduces LDL cholesterol, total cholesterol, and triglycerides in hyperlipidemic and overweight adults. Observational data link grapefruit consumption to reduced coronary heart disease mortality risk in women. The flavonoids naringenin and naringin have demonstrated antihypertensive and anti-atherosclerotic properties in clinical and preclinical research.

A DBRPCT found that 1500 mg/day of S. scardica extract (SidTea+) for 4 weeks significantly decreased systolic blood pressure by 10.8 mmHg, mean arterial pressure by 4.5 mmHg, and resting heart rate by 3.1 bpm in healthy adults. GMT also increased estimated VO2max, a key cardiovascular fitness marker. Traditional use includes treatment of angina pectoris.

Epidemiological, cohort, and RCT evidence consistently links green tea consumption with cardiovascular benefit. A systematic review and meta-analysis of 55 eligible RCTs found improvements in lipid and glycemic profiles with green tea supplementation. A large cohort study showed daily consumption of 2 cups was associated with a 22–33% reduction in CVD-cause mortality in the Japanese population. Mechanisms include antioxidative, anti-inflammatory, antihypertensive, lipid-lowering, and endothelial-protective effects of catechins.

Guarana has demonstrated multiple cardioprotective properties in human and in vitro research: inhibition of platelet aggregation (in vitro and in vivo), reduction of LDL oxidation in elderly human consumers, anti-inflammatory activity in lipotoxic models, and epidemiological association with lower cardiovascular risk biomarkers. Theobromine also uniquely influences cardiovascular function through vasodilation.

Guggulipid has been studied in multiple clinical trials for its lipid-lowering and cardioprotective effects. Earlier Indian trials (1970s–1990s) found significant reductions in total cholesterol, LDL, and triglycerides with elevations in HDL. A 2003 JAMA randomized controlled trial in U.S. patients with hypercholesterolemia failed to replicate these benefits and found LDL actually increased in some subjects. Evidence is thus mixed.

A systematic review and meta-analysis of six human studies found GS supplementation significantly decreased triglycerides, total cholesterol, LDL, and diastolic blood pressure, collectively improving cardiovascular risk factors. Evidence is secondary to metabolic effects; dedicated cardiac-outcome trials are not yet available.

Hawthorn (Crataegus spp.) has been studied in multiple randomized, placebo-controlled trials for heart health, particularly chronic heart failure and hypertension. A Cochrane-reviewed meta-analysis found significant benefits in symptom control and physiologic outcomes as adjunctive therapy for chronic heart failure. However, the large SPICE trial (2,681 patients, 24 months) did not show significant reduction in primary cardiac events in the overall CHF population, though a pre-specified subgroup showed a meaningful reduction in sudden cardiac death. The NIH/NCCIH characterizes the overall evidence as conflicting.

Hesperetin and hesperidin exert cardioprotective effects including anti-atherosclerotic, lipid-modulating, and cardiotoxicity-protective actions supported by systematic review evidence. Clinical trials support benefits on blood pressure, endothelial function, and inflammatory markers relevant to heart disease.

Hesperidin exhibits multiple cardioprotective actions supported by clinical and preclinical evidence: it reduces LDL, total cholesterol, and triglycerides; lowers SBP; improves endothelial function; and reduces inflammatory markers such as TNF-α, CRP, and adhesion molecules. A 2024 systematic review confirmed benefits in blood pressure, endothelial function, and inflammatory markers from clinical trials.

Hibiscus sabdariffa has demonstrated broad cardioprotective effects in clinical and preclinical studies, including blood pressure reduction, LDL oxidation inhibition, anti-inflammatory activity, and cardiac hypertrophy attenuation. A 2022 meta-analysis of 17 RCTs concluded HS may prevent or alleviate individual CVD risk factors.

HMR inhibited TNF-alpha production and reactive oxygen species in human monocytes and suppressed adhesion molecule expression in human aortic endothelial cells—mechanisms relevant to cardiovascular disease. Epidemiological data also link higher serum enterolactone (HMR's metabolite) with reduced cardiovascular mortality. Direct human interventional data specific to HMR remain limited.

HMR exhibits anti-inflammatory activity in human aortic endothelial cells by reducing ICAM-1 and VCAM-1 expression, inhibiting monocyte adhesion, and suppressing NF-κB signaling — all mechanisms relevant to atherosclerosis. Preclinical studies show HMR reduces LDL oxidation and atherosclerotic lesion formation. Epidemiological data associate higher enterolactone levels with lower cardiovascular risk, though human intervention trials are limited.

Clinical studies demonstrate that substituting honey for sucrose reduces multiple cardiovascular risk factors including total cholesterol, LDL-C, triglycerides, CRP, and fasting blood glucose. A 2022 GRADE-assessed meta-analysis and a 2025 umbrella review confirm modest beneficial effects on cardiometabolic markers with daily honey consumption.

Animal studies have demonstrated antiarrhythmic, vasodilatory, and antihypertensive properties of horehound diterpenes, particularly marrubenol acting as an L-type calcium channel blocker. An in vitro study showed M. vulgare extract inhibits human LDL oxidation and enhances HDL-mediated cholesterol efflux. Evidence is exclusively preclinical.

Vaccinium anthocyanins have been studied in multiple human RCTs for cardiovascular endpoints. A 2021 meta-analysis of 44 RCTs found significant reductions in LDL cholesterol and triglycerides with purified anthocyanin supplementation. Huckleberry's anthocyanin profile is consistent with the Vaccinium genus compounds studied. Mechanistic pathways include improvements in endothelial function, lipid metabolism, and inflammation.

HMR inhibits TNF-α-driven vascular endothelial inflammation, reduces ICAM-1 and VCAM-1 expression in human aortic endothelial cells, and activates Nrf2/HO-1 cytoprotective signaling—mechanisms directly relevant to atherosclerosis and cardiovascular disease. A US patent and published research endorse potential cardiovascular benefits. Evidence is currently preclinical (cell-based); human cardiovascular outcomes trials have not been completed.

Bael fruit and leaf extracts have demonstrated cardioprotective effects in isoproterenol (ISO)-induced myocardial infarction models in rats, reducing oxidative cardiac damage, restoring antioxidant status, and normalizing cardiac biomarkers. Phytochemicals including terpenoids, tannins, flavonoids, and aurapten are identified as the active cardioprotective agents.

Multiple clinical trials document that gum arabic supplementation favorably modifies cardiometabolic risk factors including blood pressure, BMI, visceral adiposity index, LDL cholesterol, and triglycerides. The 2023 systematic review confirms gum arabic's use in managing metabolic disorders relevant to cardiovascular risk.

Clinical evidence shows inositol supplementation improves multiple cardiovascular risk factors including blood pressure, lipid profile, and insulin resistance in metabolic syndrome and PCOS populations. A 2025 GRADE-assessed systematic review and meta-analysis of RCTs quantified significant improvements in cardiometabolic indices. Evidence is strongest for blood pressure reduction and lipid normalization.

IHN's lipid-lowering, blood-pressure-modulating, and fibrinolytic mechanisms converge on cardiovascular risk reduction. Clinical sources including RxList note that niacin released from IHN can lower blood fats, widen blood vessels, and break up clotting proteins—all relevant to heart disease prevention. The 2019 Circulation abstract framed IHN explicitly as an alternative to niacin for dyslipidemia-related cardiovascular disease risk. Evidence is indirect and largely inferred from component mechanisms.

Multiple preclinical studies demonstrate cardioprotective effects of I. racemosa root extract, including protection against isoproterenol-induced myocardial infarction in rats and improvement in ECG parameters in IHD human subjects. The herb shows beta-adrenergic blocking activity and antioxidant-mediated cardiac protection. Ayurveda has long classified it as a cardiac tonic (hridya).

Jiaogulan supports heart health through multiple mechanisms: lowering blood pressure and LDL/triglycerides, raising HDL, stimulating nitric oxide production, and protecting cardiac muscle cells from ischemia-reperfusion injury. Clinical and in vitro studies support these cardiovascular benefits.

Jujube's cardiometabolic evidence derives from its documented effects on blood glucose, lipids, and blood pressure — all major cardiovascular risk factors. The 2022 RCT showed significant improvements in FPG, TG, TC, and LDL-C in T2D patients over 12 weeks. Jujube polyphenols also inhibit LDL oxidation and support vascular endothelial function. Traditional medicine across Asia prescribes jujube as a cardiac tonic.

Clinical and epidemiological evidence links kale consumption to improved cardiovascular risk factors including LDL reduction, HDL elevation, and blood pressure lowering. Kale's flavonoids, fiber, potassium, and vitamin K1 content collectively support vascular health. A 12-week kale juice trial in hypercholesterolemic men showed significant improvements in the coronary artery disease risk profile.

Kelp components—fucoidan, alginate, and bioactive peptides—have demonstrated cardiovascular benefits including reductions in LDL cholesterol, blood pressure, and anti-thrombotic effects in human studies. Memorial Sloan Kettering reports that fucoidan in overweight adults over 3 months decreased diastolic blood pressure and LDL cholesterol. Evidence is emerging from small RCTs and epidemiological data from seaweed-consuming populations.

Kidney beans support cardiovascular health through LDL cholesterol reduction, blood pressure lowering, antioxidant polyphenols that protect blood vessels, and improvements in vascular tone. Human crossover studies specifically on red kidney beans have documented lower blood pressure and improved arterial stiffness measures after consumption.

Resveratrol from knotweed supports heart function through multiple mechanisms: improving flow-mediated dilation, reducing LDL oxidation, inhibiting clot formation, and lowering blood viscosity. Preclinical studies in the Polygonum genus demonstrate cardioprotective effects against myocardial injury biomarkers. Polydatin from PC has shown antihyperlipidemic effects in clinical trials.

A 2017 meta-analysis of 7 RCTs (n=662) found krill oil significantly reduced LDL cholesterol (−15.52 mg/dL) and triglycerides (−14.03 mg/dL) and raised HDL cholesterol (+6.65 mg/dL). A 2023 updated meta-analysis of 14 RCTs (n=1,458) confirmed significant reductions in total cholesterol, LDL, and triglycerides. Blood pressure was not significantly affected across trials.

Puerarin has been extensively studied and used clinically in China for cardiovascular conditions including coronary artery disease, myocardial infarction, and cardiac hypertrophy. Clinical trials demonstrate improvements in endothelial function and angina symptoms. Multiple preclinical studies support cardioprotective effects via antioxidant, anti-inflammatory, and anti-apoptotic mechanisms.

L-arginine is the principal substrate for nitric oxide (NO) synthesis in vascular endothelium; NO promotes vasodilation, inhibits platelet aggregation, and is central to vascular tone regulation. Clinical evidence from multiple randomized controlled trials and meta-analyses supports modest blood-pressure-lowering effects and improvements in endothelial function, particularly in populations with pre-existing cardiovascular or metabolic risk factors. Evidence is real but heterogeneous, and long-term cardiovascular outcome data remain limited.

A meta-analysis of 13 controlled trials (n=3,629) in acute myocardial infarction patients associated L-carnitine with a 27% reduction in all-cause mortality, 65% reduction in ventricular arrhythmias, and 40% reduction in angina. Additional trials demonstrated benefits in ventricular remodeling and heart failure symptoms.

Carnosine is naturally concentrated in cardiac muscle and plays a pH-buffering and antioxidant role in heart tissue. In humans, urinary carnosine metabolites are associated with markers of cardiovascular risk. Carnosine supplementation improved cardiometabolic risk factors (glucose, triglycerides) in T2D RCTs, though a dedicated 14-week RCT found no direct effect on endothelial function or arterial stiffness.

L-Citrulline has substantial clinical evidence supporting its role in cardiovascular health, primarily through enhancing nitric oxide (NO) bioavailability. Meta-analyses of randomized controlled trials demonstrate statistically significant reductions in both systolic and diastolic blood pressure. Clinical studies also show improvements in endothelial function (flow-mediated dilation) and benefits in heart failure patients, including improved left ventricular ejection fraction.

NAC reduces oxidative stress, a key driver of atherosclerosis, and has vasodilatory properties that may improve blood flow. Clinical evidence covers reduction of platelet aggregation, contrast-induced nephropathy prevention in cardiac procedures, and modest effects on cardiovascular biomarkers. Evidence is mechanistically strong but clinical outcome data from large trials are limited.

GSH depletion is mechanistically linked to atherosclerosis and ischemic heart disease through increased oxidative stress and reduced nitric oxide bioavailability. Human trials with sublingual L-glutathione have demonstrated improvements in lipid profiles (reduced total and LDL cholesterol) in men with cardiovascular risk factors. The broader role of GSH in cardiovascular protection is supported by multiple observational and interventional studies.

L-histidine is incorporated into histidine-tryptophan-ketoglutarate (HTK) cardioplegia solutions used globally in cardiac surgery to protect the myocardium from ischemia-reperfusion injury. Animal studies demonstrate that L-histidine reduces ventricular infarct size and arrhythmia duration following coronary ligation. Its antioxidant buffering of the imidazole ring underpins this cardioprotective mechanism.

Collagen is essential to the structure of the myocardium and cardiac valves; proline is required for cardiac collagen synthesis. The proline dehydrogenase (PRODH) enzyme, which catabolizes proline, has been shown to influence mitochondrial redox status during cardiac remodeling. Blood pressure reductions observed in collagen peptide RCTs suggest indirect cardiovascular relevance of proline-rich supplementation.

Higher dietary intakes and blood levels of LA are consistently associated with reduced risk of coronary heart disease (CHD) across large prospective cohort studies and meta-analyses. A 2014 systematic review and meta-analysis of prospective cohort studies (Farvid et al., Circulation) found a dose-response inverse association between LA intake and CHD risk. LA lowers LDL cholesterol when substituted for saturated fatty acids.

Lecithin influences cardiovascular health primarily via its role in cholesterol metabolism and reverse cholesterol transport mediated by LCAT. Evidence from animal studies and clinical reviews supports benefits in lipid profiles; direct large-scale RCT evidence in humans for hard cardiovascular endpoints remains limited. A 2024 review in a peer-reviewed cardiology journal examined the mechanistic and clinical literature.

Lemon's flavonoids, vitamin C, and citric acid contribute to cardiovascular protection through antioxidant, lipid-lowering, and antihypertensive effects documented in clinical studies. Citrus flavonoids reduce LDL oxidation, lower blood pressure, and decrease inflammatory markers associated with cardiovascular risk.

LEM demonstrates cardioprotective potential via its hypocholesterolemic and anti-atherogenic effects in preclinical models. In a rabbit atherosclerosis model, LEM reduced atherosclerotic lesions significantly. Eritadenine modifies lipid profiles and homocysteine metabolism, both cardiovascular risk factors. Human clinical evidence remains limited.

Prospective cohort data from over 214,000 participants found that higher lignan intake was associated with a significantly lower risk of coronary heart disease (pooled HR 0.85 for total lignans). Intervention studies using flaxseed lignan supplements showed beneficial associations with C-reactive protein, and a meta-analysis suggested lignans lower plasma total and LDL cholesterol. Evidence is strongest from dietary exposure studies; isolated lignan supplement trials are fewer and more mixed.

Multiple lines of evidence link lime and broader citrus intake to reduced cardiovascular risk. Lime's vitamin C, flavonoids, and antioxidants reduce LDL oxidation, lower cholesterol and triglycerides, and modestly reduce diastolic blood pressure. Epidemiological data from cohort studies support an inverse relationship between citrus flavonoid intake and cardiovascular mortality.

L. gracile ethanol extract has demonstrated vasorelaxant activity in isolated rat aortic tissue via an endothelium-dependent NO-cGMP signaling pathway. Constituent flavonoids (e.g., vitexin) show myocardial protective effects in published studies. Antiplatelet activity has also been reported for L. gracile extract in vitro. All evidence is preclinical.

Lotus seed alkaloids protect the cardiovascular system through antihypertensive, anti-arrhythmic, antioxidant, and anti-inflammatory mechanisms in animal models. TCM assigns lotus seed to the Heart meridian and uses it to nourish the heart. Human clinical data are not available.

Multiple large observational studies and a systematic review/meta-analysis in nearly 400,000 participants associate higher lutein intake or blood levels with meaningfully lower risks of coronary heart disease and stroke. Mechanistic research identifies antioxidant, anti-inflammatory, and anti-atherosclerotic pathways—including reduced carotid intima-media thickness, lower proinflammatory cytokines, and inhibited monocyte recruitment to arterial walls. Evidence is predominantly observational; large-scale cardiovascular-outcome RCTs are still lacking.

Luteolin has been identified as a cardioprotective agent that reduces cardiac hypertrophy, fibrosis, and dysfunction in preclinical models. Human RCT data using luteolin-containing nutraceuticals show improvements in cardiovascular biomarkers including carotid-media thickness and endothelial function.

Lychee fruit and its polyphenol extracts have demonstrated multiple cardioprotective properties in vitro and in animal models, including antioxidant protection of vascular tissue, ACE-inhibitory effects, potential LDL-cholesterol lowering, and anti-atherosclerotic action. Oligonol's human clinical program claims cardiovascular health support through effects on blood flow, visceral fat, and oxidative stress. Lychee's potassium and magnesium content also support standard dietary cardiovascular benefit.

Lycopene, a carotenoid predominantly found in tomatoes, has substantial human and clinical evidence supporting a role in cardiovascular disease prevention. Multiple systematic reviews and meta-analyses link higher lycopene intake or serum levels to reduced CVD risk, lower LDL oxidation, improved endothelial function, and modest blood pressure reduction. Results across individual trials are not always consistent, but the overall body of evidence is clearly in the scientific domain.

Clinical and epidemiological evidence supports macadamia nut consumption for reducing cardiovascular disease risk. A review of six studies found macadamia nuts decreased CVD risk factors including cholesterol, inflammation, and oxidative stress. Research suggests regular intake may help prevent coronary artery disease. The primary mechanism is the MUFA-rich fatty acid profile favorably modifying lipid and lipoprotein concentrations.

Magnesium has substantial clinical and epidemiological evidence supporting its role in cardiovascular health. Higher dietary and circulating magnesium levels are inversely associated with risks of coronary heart disease, stroke, and total cardiovascular disease. Magnesium supplementation produces modest but significant reductions in blood pressure, and magnesium deficiency is linked to cardiac arrhythmias including atrial fibrillation. The evidence base spans multiple large meta-analyses and randomized controlled trials.

Preclinical studies in rats link maitake consumption to reduced total cholesterol, triglycerides, and systolic blood pressure, and to improved hepatic cholesterol metabolism. A double-blind human study reportedly found reductions in blood pressure and lipids in hypertensive patients over 12 weeks. Broader mushroom systematic reviews show limited but suggestive evidence for cardiometabolic benefit.

A 2025 RCT in postmenopausal women found daily mango consumption (~330 g for 2 weeks) significantly reduced systolic blood pressure by ~6 mmHg and LDL cholesterol by ~12.6 mg/dL. An 8-week RCT found mango with avocado improved flow-mediated vasodilation in prediabetic adults, an indicator of endothelial and arterial health.

A human prospective cohort study in high cardiovascular-risk patients (Framingham Score) given 2,520 mg/day G. mangostana extract for 90 days showed significantly reduced MDA (lipid peroxidation) and increased SOD, suggesting anti-atherogenic antioxidant effects. Animal studies demonstrate LDL/triglyceride reduction and foam cell inhibition. Xanthones exhibit antiplatelet, vasorelaxant, and cardioprotective properties in preclinical models.

Maqui's anthocyanins reduce oxidized LDL in human RCTs and significantly lower LDL cholesterol in a 3-month clinical trial in prediabetic adults. Epidemiological data on dietary anthocyanins link higher intake to a 32% lower heart attack risk and 12% reduced hypertension risk. Maqui also contains potassium, supporting vascular function.

Preclinical studies demonstrate cardioprotective effects of marjoram extract, including reduction of myocardial injury markers and anti-ischemic activity in rat models. Marjoram has been traditionally used in Moroccan and Iranian medicine for cardiac complaints.

Clinical and epidemiological evidence links lower endogenous melatonin levels with increased cardiovascular disease risk, including hypertension and heart failure. RCTs show melatonin can reduce nocturnal blood pressure and may modulate markers associated with ischemia-reperfusion injury. However, large-scale clinical outcome trials remain lacking.

MeCbl lowers homocysteine—an independent cardiovascular risk factor—by acting as cofactor for methionine synthase. Randomized controlled evidence supports homocysteine reduction with methylcobalamin-containing B-vitamin formulations. However, lowering homocysteine has not been definitively shown to reduce hard cardiovascular endpoints in all populations.

Robust meta-analytic evidence links millet seed consumption to simultaneous reductions in total cholesterol, LDL-C, triglycerides, BMI, and blood pressure—all established cardiovascular risk factors. Millets have anti-atherosclerogenic properties attributed to their fiber, phytosterols, PUFAs, and anti-inflammatory polyphenols.

Momordica charantia has been studied for cardioprotective properties primarily via its effects on glycaemia, lipids, oxidative stress, and blood pressure. Momordicine I, a key cucurbitane triterpenoid, has received specific attention for cardiovascular benefits. Clinical human evidence is limited but exists in the context of metabolic risk factor modification.

M. citrifolia noni extracts demonstrate cardiovascular benefits through multiple mechanisms: antihypertensive effects via eNOS activation, antidyslipidaemic effects (reduced cholesterol, LDL, triglycerides), antioxidant protection of endothelial cells against AGE-induced damage, and anti-inflammatory reductions in hs-CRP. Clinical trial evidence supports lipid and inflammation benefits.

Morus alba simultaneously addresses multiple cardiovascular risk factors—blood pressure, cholesterol, triglycerides, and CRP—across human RCTs. The 2025 meta-analysis of 15 RCTs confirmed pooled benefits on lipid profiles and inflammatory markers associated with cardiovascular risk.

Motherwort has documented cardiotonic, antiarrhythmic, and cardioprotective properties supported by both clinical use and experimental evidence. Its alkaloids (leonurine, stachydrine) and flavonoids exert negative chronotropic, hypotensive, and antioxidant effects on cardiac tissue. Germany's Commission E and the European Medicines Agency (EMA) endorse it for mild cardiac complaints of nervous origin.

Mulberry modulates multiple cardiovascular risk factors—blood pressure, LDL cholesterol, triglycerides, and inflammation—in clinical trials. Preclinical evidence suggests anti-atherosclerotic properties including reduced arterial plaque formation. The 2025 meta-analysis of 15 RCTs confirmed broad cardiometabolic benefit.

Mustard seeds contain omega-3 fatty acids (ALA), plant sterols, and glucosinolate-derived compounds associated with cardiovascular protection. The seed's ALA content and isothiocyanates are linked to reduced LDL oxidation, improved endothelial function, and anti-inflammatory effects relevant to atherosclerosis. PMC reviews document these cardioprotective mechanisms, though dedicated long-term human RCT data are limited.

A systematic review of TC evidence found significant cardioprotective effects through antioxidant, anti-inflammatory, and lipid-lowering properties, including blood pressure reduction and modulation of oxidative stress markers. A 12-week human RCT in type 2 diabetic patients showed TC improved endothelial dysfunction, a key cardiovascular risk factor.

NAC has multiple documented cardiovascular effects in human studies, including lowering plasma homocysteine, modest blood pressure reduction, anti-platelet activity, and protection against contrast-induced nephropathy in cardiac patients. Two double-blind RCTs found that 1.8 g/day NAC for 4 weeks significantly reduced plasma homocysteine and systolic blood pressure. Perioperative IV NAC has also been studied in cardiac surgery populations.

Naringin protects myocardial function, reduces infarct size, and attenuates ischemia-reperfusion injury in multiple animal models. A 2025 systematic review of 62 studies confirmed cardioprotective mechanisms across cellular, animal, and limited human models. Human trials show improved lipid profiles and arterial stiffness. Mechanistic pathways include PI3K/Akt, NF-κB, Nrf2, and renin-angiotensin system modulation.

Nattokinase is a fibrinolytic serine protease extracted from natto (fermented soybeans) with documented activity against cardiovascular risk factors in multiple human clinical trials. The strongest and most consistent evidence supports a blood pressure-lowering effect, confirmed across randomized controlled trials and a 2023 systematic review/meta-analysis. Evidence for lipid-lowering and anti-atherosclerotic effects exists but is more dose-dependent and less conclusive at lower doses.

Nattokinase has documented cardiovascular benefits including antihypertensive, fibrinolytic, antiplatelet, and anti-atherosclerotic actions collectively relevant to heart health. High natto consumption in Japanese populations is epidemiologically associated with reduced CVD mortality. Multiple human clinical studies have evaluated these effects.

NAD+ levels are depleted in the failing human heart, and NR supplementation has been studied in clinical trials to restore myocardial NAD+ and improve mitochondrial function in heart failure. A human study of NR at 2 g/day for 12 weeks in ambulatory HFrEF patients found NR was safe, elevated whole-blood NAD+, and correlated with reduced systemic inflammation. Mechanistic studies in LVAD patients are underway to directly assess myocardial NAD+ and mitochondrial function.

Preclinical studies demonstrate NMN alleviates heart failure, myocardial ischemia/reperfusion injury, and atrial fibrillation through NAD+-dependent mechanisms. Human clinical data show NMN is safe with respect to cardiac biomarkers and ECG parameters. NMN improves myocardial hemodynamic parameters and reduces oxidative stress in aged animal hearts.

A meta-analysis of RCTs found that Opuntia ficus-indica supplementation produced significant reductions in both systolic and diastolic blood pressure, as well as improvements in cholesterol and triglycerides. These cardiovascular risk factor improvements are supported by multiple human trials. The polyphenol content of nopal is considered to contribute to vascular benefits. Evidence is moderate, primarily from short-term studies.

Oat consumption is associated with reduced cardiovascular disease (CVD) risk through LDL cholesterol lowering, blood pressure reduction in some populations, and anti-inflammatory effects via avenanthramides. The FDA's 1996 health claim recognized oats' role in CVD risk reduction. Multiple systematic reviews confirm these cardiometabolic benefits.

Okra has demonstrated cardiometabolic benefits in clinical trials including reductions in total cholesterol, LDL-C, and fasting blood glucose—all established cardiovascular risk factors. Preclinical evidence also identifies vasoprotective and anti-inflammatory activity via modulation of LOX-1/NF-κB signaling. Overall cardiovascular benefit in humans is inferred from surrogate marker improvements rather than direct endpoint trials.

OA protects the heart from hyperglycemia-induced contractile dysfunction, ischemia-reperfusion injury, and oxidative damage in cardiac myoblasts and isolated rat hearts. It reduces cardiac apoptosis and oxidative stress and has been described as a novel cardioprotective triterpenoid.

The FDA issued a qualified health claim that oleic acid in edible oils may reduce the risk of coronary heart disease when substituted for saturated fats. Multiple RCTs show oleic acid lowers LDL cholesterol and improves HDL-to-total-cholesterol ratios. Large cohort and dietary intervention studies consistently support a protective role for dietary oleic acid intake on coronary heart disease outcomes.

Olive and olive leaf extract have robust human clinical evidence for multiple cardiac risk factor improvements: blood pressure reduction, LDL cholesterol lowering, triglyceride reduction, and oxidized LDL attenuation. The EFSA has approved a health claim for olive oil polyphenols protecting blood lipids from oxidative damage. The Mediterranean diet evidence base for cardiovascular protection is extensive.

Olive oil, especially EVOO, is one of the most evidence-backed dietary components for cardiovascular protection. The landmark PREDIMED trial demonstrated significant reductions in major cardiovascular events with daily EVOO use. Multiple meta-analyses confirm an inverse dose-response between olive oil consumption and cardiovascular mortality. EVOO polyphenols protect LDL from oxidation, improve endothelial function, and modulate several cardiac risk factors.

Omega-3 fatty acids (EPA and DHA) have extensive clinical evidence supporting their role in cardiovascular health, primarily through robust triglyceride-lowering effects and, at high doses of purified EPA, significant reductions in major cardiovascular events. The landmark REDUCE-IT trial demonstrated a 25% relative risk reduction in cardiovascular outcomes with 4 g/day of icosapent ethyl (purified EPA). However, evidence for standard-dose EPA+DHA supplements on hard cardiovascular endpoints (MI, stroke, mortality) remains inconsistent across large meta-analyses, distinguishing high-dose EPA monotherapy from conventional fish oil supplementation.

Omega-6 fatty acids, primarily linoleic acid (LA), have been extensively studied in relation to cardiovascular disease risk. Aggregate evidence from randomized controlled trials, prospective cohort studies, and meta-analyses indicates that replacing saturated fat with omega-6 PUFAs reduces LDL cholesterol and is associated with lower coronary heart disease risk. However, evidence from isolated RCTs on hard cardiovascular endpoints remains of low certainty, and some debate persists around high omega-6 intake and inflammation.

Omega-7 fatty acids (palmitoleic acid) have been associated with improvements in cardiovascular risk markers—including CRP, LDL, triglycerides, and HDL—in both interventional trials and epidemiological studies. An NIH-registered Phase 2 clinical trial is actively investigating omega-7-rich oil on lipoprotein metabolism in humans. Evidence is encouraging but remains preliminary, with no large-scale cardiovascular outcomes trial completed for omega-7 specifically.

Diets rich in omega-9 oleic acid, particularly via extra-virgin olive oil, are associated with reduced major cardiovascular events in large randomized trials. Oleic acid modulates endothelial function and reduces LDL oxidation. The PREDIMED trial demonstrated approximately 30% reduction in major cardiovascular events with an olive oil-enriched Mediterranean diet. Evidence is partly confounded by the full dietary pattern rather than oleic acid in isolation.

Onion exerts cardioprotective effects through a combination of mechanisms: reducing LDL and total cholesterol, inhibiting platelet aggregation, lowering blood pressure, and reducing systemic inflammation. A meta-analysis of 10 RCTs confirmed significant improvements in HDL, LDL, and total cholesterol with onion supplementation. Human trials demonstrate reductions in cardiovascular risk biomarkers.

Ophiopogon japonicus is a core ingredient of Shengmai injection, a clinically used Chinese patent medicine for heart failure. A meta-analysis of 20 RCTs (n=1,562) found Shengmai injection significantly improved left ventricular ejection fraction and cardiac output versus Western medicine alone. Steroidal saponins from the plant also attenuate doxorubicin-induced cardiomyocyte injury in preclinical studies.

Ophiopogon root is a key ingredient in clinically used Chinese patent medicines (Shengmai/Shenmai/YiQiFuMai injections) that have been tested in randomized controlled trials for heart failure and coronary heart disease. Preclinical studies confirm direct cardioprotective effects of steroidal saponins and ophiopogonin D against doxorubicin-induced cardiomyopathy. Clinical RCT data from CHF trials shows improved NYHA classification, ejection fraction, and 6-minute walk distance.

Orange flavonoids, particularly hesperidin, have demonstrated cardiovascular-protective effects in human RCTs, including reductions in LDL cholesterol, CRP, and adhesion molecules. A 2024 meta-analysis of 12 RCTs found significant decreases in total and LDL cholesterol. Hesperidin also improves endothelial function and blood pressure in hypertensive individuals.

Carvacrol from oregano has been shown in preclinical studies to reduce heart rate, systolic and diastolic blood pressure, and alter lipid profiles favorably. A small human study found that oregano extract reduced LDL cholesterol and raised HDL cholesterol in people with mildly elevated cholesterol. Animal and mechanistic studies suggest antioxidant protection of LDL against oxidation and anti-inflammatory effects on cardiac tissue.

Clinical and experimental evidence indicates that brown rice, rice bran, and rice bran oil reduce cardiovascular risk factors including hypercholesterolemia and oxidative stress. Rice bran policosanol extract has shown antiplatelet activity in vitro, and γ-oryzanol has antioxidant effects on cardiac tissue.

Multiple human studies link oyster mushroom intake to improvements in cardiometabolic risk markers including LDL cholesterol, triglycerides, blood pressure, and fasting glucose. The 2020 systematic review (8 trials) concluded that P. ostreatus may improve cardiometabolic health. Traditional use across Asian medicine also recognizes the cardiovascular protective role.

Clinical evidence on palm oil and heart health is contested. As a dietary fat, palm oil raises LDL cholesterol compared to unsaturated oils, and one case-control study linked habitual palm oil cooking to higher nonfatal myocardial infarction risk versus soybean oil. However, systematic reviews find no strong evidence establishing palm oil as uniquely atherogenic relative to other saturated fats, and the tocotrienol fraction has shown cardioprotective properties in clinical studies.

Clinical and observational evidence consistently links elevated dietary and circulating palmitic acid with increased cardiovascular risk, including higher LDL-cholesterol and major adverse cardiac events. In a cohort of 1,040 coronary heart disease patients, high serum palmitic acid was associated with significantly lower survival and higher rates of MACE. The mechanism involves endothelial injury via protein palmitoylation and upregulation of inflammatory pathways.

POA supplementation studies show improvements in key cardiac risk factors including reductions in LDL-cholesterol, triglycerides, and hs-CRP. Prospective cohort data linking higher POA to lower myocardial infarction risk are encouraging, though some cohort data also associate esterified POA with heart failure risk.

Pantethine's lipid-lowering effects across more than 28 controlled clinical trials position it as a clinically studied cardiovascular supplement for patients at risk of coronary heart disease. Reductions in LDL-C, total cholesterol, non-HDL-C, and triglycerides are the primary documented mechanisms of cardiac benefit. A published case report also documented pantethine therapy rescuing end-stage heart failure in an infant with CoA biosynthesis deficiency.

Preclinical studies show papaya extracts reduce total cholesterol, LDL, and triglycerides while raising HDL, and decrease atherogenic index in animal models of dyslipidemia. The American Heart Association recognizes papaya's lycopene content as potentially reducing heart disease and stroke risk, and its fiber content as supporting cholesterol management. Formal human RCTs targeting cardiovascular endpoints are limited.

Multiple lines of preclinical evidence support parsley as a cardioprotective agent: antithrombotic, antihypertensive, and hypolipidemic effects have each been demonstrated in animal models. Folate from parsley also reduces homocysteine, a recognised cardiovascular risk marker. Clinical human trials are still needed to confirm these effects.

Pea-derived bioactive peptides, fiber, and phytonutrients have demonstrated cardiovascular benefits including improved lipid profiles (lower total cholesterol, LDL, triglycerides; higher HDL), ACE-inhibitory and blood pressure-lowering activity, and antioxidant effects in human and animal studies.

Peach extracts have demonstrated cardiovascular-relevant activity in preclinical models, including inhibition of angiotensin II-induced vascular signaling and anti-inflammatory effects relevant to atherosclerosis. Peach kernel (Tao Ren) has been used in TCM for atherosclerosis. Evidence is mostly preclinical.

Peanuts carry an FDA qualified health claim for heart disease risk reduction at 1.5 oz/day. Multiple RCTs and meta-analyses demonstrate beneficial effects on LDL cholesterol, TC:HDL ratio, and triglycerides. A randomised crossover trial in hypercholesterolaemic men showed 77 g/day peanuts significantly improved LDL/HDL and total/HDL ratios and raised HDL-C.

Epidemiological data consistently link pear and apple intake to reduced risk of cardiovascular disease and cardiovascular death. Pear polyphenols — catechins, chlorogenic acid, quercetin — support vascular endothelial function, reduce LDL oxidation, and exert anti-inflammatory effects on cardiac tissue. A meta-analysis found significant inverse associations between apple/pear intake and cerebrovascular disease and cardiovascular mortality.

Pectin reduces multiple cardiovascular risk factors including LDL cholesterol, total cholesterol, fibrinogen network abnormality, and blood pressure. Clinical trials specifically document significant lipid-lowering effects. Pectin's impact on gut microbiota also supports cardiovascular benefits through SCFA-mediated pathways.

Perilla frutescens leaf powder in a 6-month human RCT reduced oxidized LDL and blood pressure—two major cardiovascular risk factors. Seed oil ALA provides cardiovascular protective effects through lipid-lowering and anti-inflammatory mechanisms. Rosmarinic acid demonstrates cardioprotective effects by inhibiting oxidative damage in cardiomyocytes.

Berberine from P. amurense has demonstrated cardiovascular benefits in clinical trials including improvements in lipid levels, blood pressure, and fasting glucose—all established cardiovascular risk factors. An 8-week RCT in osteoarthritis patients with a P. amurense plus citrus extract found broad improvements in cardiovascular risk biomarkers. Berberine has also been studied in congestive heart failure.

PC metabolism via gut microbiota generates TMAO, a metabolite clinically associated with increased cardiovascular risk in large cohort studies. Conversely, PC supports HDL function via LCAT and homocysteine reduction via betaine. The cardiovascular relationship of PC is bidirectional and dose/context dependent.

Phytosterols have robust clinical and regulatory-level evidence for reducing LDL cholesterol, a primary modifiable risk factor for cardiovascular disease. Their primary mechanism is competitive inhibition of intestinal cholesterol absorption, reducing it by 30–50%. Multiple randomized controlled trials and meta-analyses consistently show ~8–15% LDL reductions at doses of 1.5–3 g/day, leading both the FDA and EFSA to authorize heart-health claims. However, no large-scale RCT has yet demonstrated a reduction in hard cardiovascular endpoints (e.g., myocardial infarction), and some evidence suggests elevated circulating phytosterol levels may carry atherogenic risk.

Pine bark extract (Pycnogenol) has been shown in multiple RCTs to improve cardiovascular health markers including endothelial function, blood pressure, LDL cholesterol, and platelet aggregation. A systematic review of 39 RDP trials confirmed cardiovascular health as a primary indication. It also slows atherosclerosis progression in clinical studies.

Multiple RCTs demonstrate Pycnogenol lowers blood pressure, reduces LDL cholesterol, improves endothelial function, inhibits platelet aggregation, and slows atherosclerosis progression. A meta-analysis confirmed significant reductions in systolic and diastolic blood pressure and LDL-cholesterol. These cardiovascular benefits are among the best-documented effects of the extract.

Bromelain exhibits fibrinolytic and antithrombotic properties—stimulating plasminogen-to-plasmin conversion and inhibiting platelet aggregation—that support cardiovascular health. Early human studies in cardiac patients reported near-complete elimination of thrombosis. It also degrades AGE receptors linked to vascular damage.

Plant sterols have robust clinical trial and meta-analysis support for lowering LDL cholesterol, a key cardiovascular risk factor, primarily by competitively inhibiting cholesterol absorption in the small intestine. At approximately 2 g/day, they reduce LDL-C by 8–10%, and both the FDA and ESC/EAS guidelines recognize this effect. However, no large RCT has demonstrated a reduction in hard cardiovascular endpoints (e.g., heart attacks), and emerging genetic evidence raises questions about whether elevated circulating plant sterol levels may carry atherogenic risk.

Platycodon exhibits cardiovascular protective effects in preclinical studies, including protection of vascular endothelial cells from oxidized LDL injury, antihypertensive effects in spontaneously hypertensive rats, and reduction of dyslipidemia. Saponin and ethyl acetate fractions are the primary active components studied.

Policosanol, a mixture of long-chain aliphatic alcohols extracted primarily from sugarcane wax, has been clinically studied for cardiovascular benefit through two main pathways: lipid-lowering (reducing LDL and total cholesterol, raising HDL) and antiplatelet activity. Early Cuban RCTs reported striking cholesterol reductions comparable to statins, but subsequent independent trials outside Cuba found no significant lipid effect, creating a contested and geographically inconsistent evidence base. Additional mechanisms — including inhibition of LDL oxidation, platelet aggregation, and smooth muscle cell proliferation — have been documented in human studies, though hard cardiovascular endpoint data (cardiac events, mortality) remain absent.

Substantial clinical evidence supports pomegranate's cardioprotective effects via LDL oxidation protection, blood pressure reduction, improved endothelial function, and anti-atherosclerotic action. A 2025 comprehensive review and multiple RCTs document benefits across multiple cardiovascular risk markers. Pomegranate is superior to many antioxidants in protecting LDL and HDL from oxidation.

Pomelo contains potassium, fiber, and flavonoids that collectively support cardiovascular function. Animal studies demonstrate correction of diet-induced cardiovascular dysfunction including reduced atherogenic indices, improved lipid profiles, and anti-inflammatory vascular effects via naringin. Pomelo peel oil has been studied for protection against ischemia-reperfusion cardiac injury in animal models.

Potassium has robust clinical and epidemiological evidence supporting its role in cardiovascular health, primarily through blood pressure regulation and cardiac electrophysiological stability. Increased potassium intake significantly lowers blood pressure in hypertensive individuals and is associated with reduced stroke risk. Dyskalemia — both low and high potassium — is linked to cardiac arrhythmias and elevated cardiovascular mortality. The WHO formally recommends increased dietary potassium intake to reduce cardiovascular disease and stroke risk.

Evidence from human trials and meta-analyses shows Opuntia reduces several cardiovascular risk factors simultaneously: total cholesterol, LDL, triglycerides, blood pressure, and body fat percentage. Antioxidant betalains also inhibit ICAM-1 expression and protect LDL from oxidation. No direct outcomes trials (mortality or events) have been completed.

Propionyl-L-Carnitine (PLC) has been studied in multiple human clinical trials for heart-related conditions including congestive heart failure (CHF) and stable angina. Evidence shows it can improve exercise capacity and oxygen consumption in CHF patients, and increase exercise tolerance and time to ischemic threshold in angina patients, primarily through metabolic and peripheral muscle mechanisms. However, the largest Phase III trial in CHF did not meet its primary endpoint in the overall population, limiting the strength of conclusions.

Multiple RCTs demonstrate prunes improve cardiovascular risk biomarkers including antioxidant capacity, inflammatory markers, cholesterol levels, and blood pressure in postmenopausal women and older men. A randomized controlled study (Hooshmand, J Med Food, 2021) found 50 g/day for 6 months raised HDL, reduced inflammation, and improved antioxidant status. Prune polyphenols inhibit LDL oxidation in vitro, a key step in atherogenesis.

Prunus domestica consumption is associated with improved cardiovascular risk factors in human studies, including reduced TC, increased HDL-c, lowered inflammatory biomarkers (IL-6, TNF-α), and reduced oxidative stress. A systematic review concluded that plum and prune consumption is associated with improved cardiovascular risk factors. The polyphenol and fiber content provides the mechanistic basis.

Psyllium husk has robust clinical and regulatory support for cardiovascular health, primarily through LDL cholesterol reduction. Multiple systematic reviews and meta-analyses of randomized controlled trials confirm significant reductions in LDL-C, non-HDL cholesterol, apolipoprotein B, and blood pressure. The U.S. FDA has authorized a coronary heart disease risk-reduction health claim for psyllium since 1998, and Health Canada has issued a similar approval.

Preclinical studies demonstrate cardioprotective and anti-atherogenic effects of P. marsupium, including improved lipid profiles and reduced aortic lipid infiltration in high-fat diet models. It is also described as a cardiac tonic in Ayurvedic tradition.

Pumpkin seed oil (PSO) is rich in unsaturated fatty acids, phytosterols, and tocopherols with documented cardioprotective effects including reductions in LDL cholesterol, blood pressure, and oxidative LDL modification. Pumpkin flesh provides potassium and fibre, both linked to cardiovascular risk reduction. Human and animal studies support these mechanisms.

Preclinical studies have shown that B. diffusa ethanolic extract (BDE) attenuates angiotensin II-induced cardiac hypertrophy and fibrosis in rats, reducing cardiac injury markers and oxidative stress. A related in vitro study in cardiomyoblast cells confirmed mitochondrial protection. Traditional Ayurvedic texts (classical name 'Hrudrogajit') describe it as useful in cardiac disorders.

Purslane consumption has been shown in multiple RCTs and meta-analyses to reduce triglycerides, total cholesterol, and CRP, while raising HDL-C, collectively improving cardiovascular risk profiles. Its high omega-3 content (particularly alpha-linolenic acid) is the primary proposed mechanism. Blood pressure reductions have also been observed in RCT meta-analyses.

In rodent models, PQQ reduced myocardial infarct size by ~50% in ischemia/reperfusion models and protected cardiac mitochondria from oxidative injury. In humans, PQQ lowered CRP and IL-6 and improved lipid peroxide levels, addressing modifiable cardiovascular risk factors. No completed human RCT for primary cardiac endpoints exists.

Quercetin, a widely distributed dietary flavonoid, has clinical and meta-analytic evidence supporting modest cardiovascular benefits, particularly reductions in blood pressure and oxidized LDL. Multiple randomized controlled trials and meta-analyses confirm statistically significant, though modest, antihypertensive effects, especially at doses above 500 mg/day. Evidence for lipid lowering is more mixed, and most mechanistic data still derive from preclinical studies.

Quillaja saponins have demonstrated cholesterol-lowering effects in a human clinical study, providing indirect cardiovascular benefit. In vitro and animal data further support reduction of cholesterol bioaccessibility and triglycerides. No direct cardiovascular outcome trials (e.g., MACE, arterial stiffness) exist for Quillaja.

Clinical evidence shows quinoa consumption lowers total cholesterol, LDL, and triglycerides—established CVD risk markers. A 2022 meta-analysis of eight human studies confirmed significant improvements in lipid profiles. Blood pressure reductions were also observed in an RCT in impaired glucose tolerance subjects. Quinoa's unsaturated fatty acids, fiber, and antioxidant polyphenols contribute to cardiovascular risk reduction.

Red raspberry polyphenols (anthocyanins, ellagitannins) show cardiovascular protective effects in preclinical models, including attenuation of heart failure-associated cardiac remodeling, reduced LDL oxidation, improved antioxidant status, and blood pressure effects. In human epidemiological and berry intervention studies, raspberry consumption is linked to improved cardiovascular risk profiles. Mechanistic evidence in animal models is strong; dedicated large-scale human RCTs specific to raspberry and cardiovascular endpoints are limited.

Red clover isoflavones have been studied in multiple RCTs for cardiovascular effects including arterial compliance, lipid profile, and blood pressure. Benefits are most consistent for improved arterial elasticity; effects on lipids are mixed across trials but a 2020 meta-analysis found a significant reduction in total cholesterol. Overall, cardioprotective effects appear modest and primarily relevant to peri/postmenopausal women.

Red yeast rice (RYR) contains monacolin K, a compound chemically identical to the prescription statin lovastatin, which inhibits HMG-CoA reductase — the rate-limiting enzyme in hepatic cholesterol synthesis. Multiple randomized controlled trials and meta-analyses demonstrate that standardized RYR preparations reduce LDL-C by 15–25% within 6–8 weeks. A large landmark Chinese RCT (Xuezhikang, ~5,000 post-MI patients) found a 45% reduction in recurrent heart attack risk and roughly one-third reduction in cardiovascular mortality over five years.

Rehmannioside compounds from Rehmannia have demonstrated cardiovascular protective effects by reducing ROS, suppressing TNF-α and IL-6, and protecting vascular endothelium in preclinical models. A 2023 ScienceDirect pharmacological review describes Rehmannia's cardiovascular and cerebrovascular protective actions as well-characterised. Traditional TCM use assigns Rehmannia to the heart channel for treating palpitations and blood deficiency.

R. glutinosa polysaccharides exhibit cardioprotective and antioxidant activities in preclinical studies. The herb reduces vascular inflammation (lowering TNF-α, IL-6, MCP-1, MDA) and lipid levels in diabetic mouse models and has documented pharmacological actions on the cardiovascular system. TCM applications include coronary heart disease in postmenopausal women.

Traditional Chinese medicine has used reishi for cardiovascular support for over 2,000 years. Human trials in clogged arteries showed reishi extract reduced chest pain and shortness of breath. Preclinical data show LDL reduction, triglyceride lowering, and antioxidative protection of LDL. The Cochrane review (2015) found reishi did not significantly reduce cholesterol or blood pressure in RCTs, emphasising weak clinical effect on surrogate markers despite preclinical plausibility.

Resveratrol, a polyphenol found in grapes and berries, has been extensively studied for cardiovascular benefits. Preclinical evidence is robust, showing protective effects against atherosclerosis, hypertension, and ischemic heart disease. Human clinical trials exist but have yielded mixed results, with the strongest signal being improvement in endothelial function (flow-mediated dilation); effects on blood pressure and lipids remain inconsistent across RCTs. Overall, clinical evidence is promising but not yet conclusive.

Rhodiola rosea demonstrates cardioprotective effects in pre-clinical models, including prevention of stress-induced cardiac damage, reduction of myocardial catecholamines and cAMP, and anti-arrhythmic activity via mu-opioid receptor activation. A 2025 Frontiers in Pharmacology systematic review and meta-analysis found standardized Rhodiola injection improved cardiac function and reduced inflammation in Chinese patients with heart failure with reduced ejection fraction (HFrEF). Evidence is strongest from pharmacological studies and Chinese clinical trials using injectable salidroside preparations.

Rosehip supplementation has demonstrated reductions in blood pressure, total cholesterol, and LDL in clinical trials. A 6-week RCT in 31 people consuming 40 g rosehip powder daily showed significant reductions in blood pressure, total cholesterol, and LDL. Mechanistically, rosehip flavonoids, lycopene, and polyphenols provide antioxidant protection to the cardiovascular system.

A randomized double-blind crossover RCT in 31 obese individuals found that 40 g/day rose hip powder for 6 weeks significantly reduced systolic blood pressure (−3.4%), total cholesterol (−4.9%), LDL cholesterol (−6.0%), and cardiovascular risk score (−17%). Animal models show rose hip reduces atherosclerotic plaque formation and increases nitric oxide-mediated vascular dilation. These findings suggest a modest but meaningful cardioprotective role.

Rosmarinic acid has demonstrated cardioprotective properties in preclinical models, including angiotensin-converting enzyme (ACE) inhibition, vasodilation, reduction of oxidative-stress-related cardiac damage markers, and improvement of cardiac lipid profiles in fructose-fed hypertensive rats. RA also exhibits lipid-lowering effects via reverse cholesterol transport modulation.

Multiple RCTs and meta-analyses show RJ modestly reduces total cholesterol and LDL, with anti-inflammatory and antioxidant effects relevant to cardiovascular risk. Animal studies show RJ retards atheroma formation. No dedicated cardiovascular outcome trial (MACE endpoints) has been conducted.

Rutin exerts cardioprotective effects through multiple mechanisms: blood pressure reduction, antithrombotic activity, cholesterol lowering, and direct antioxidant protection of cardiac tissue. Preclinical studies show improved ECG parameters and reduced infarct size; human RCTs demonstrate cardiometabolic biomarker improvements in diabetic populations.

Whole-grain rye is associated with improved lipid profiles, lower blood pressure, and reduced inflammation—all cardiovascular risk factors. Epidemiological studies report reduced coronary heart disease risk with higher cereal fiber intake. Clinical trials support transient LDL-cholesterol reduction and favorable lipid biomarker associations in metabolic syndrome patients consuming rye.

Safflower has been used in TCM for over 2,500 years to promote cardiovascular circulation. Modern evidence shows safflower oil reduces LDL and total cholesterol (highest-ranked in a 54-trial network meta-analysis), while HSYA and seed polyphenols show vasodilatory, antiplatelet, and anti-atherogenic effects. Clinical and preclinical studies support improvements in multiple cardiovascular risk factors.

A large meta-analysis of 32 RCTs (n=1,674) found saffron significantly reduced total cholesterol, LDL, triglycerides, and systolic blood pressure. Crocin and crocetin contribute to vasodilation and anti-atherosclerotic effects. Saffron has a well-documented cardiovascular-protective profile spanning lipid modulation, blood pressure reduction, and anti-inflammatory action.

Clinical research indicates schisandra may be beneficial for congestive heart failure. Animal and cell studies show schisandra lignans lower blood pressure, reduce heart tissue scarring, and exert cardioprotective effects. It protects against doxorubicin-induced cardiotoxicity in preclinical models. TCM traditionally uses schisandra for heart palpitations and cardiovascular tonification.

Schisandrin B demonstrates cardioprotective effects in multiple preclinical models, including protection against anthracycline-induced cardiotoxicity via mPTP inhibition and Nrf2 activation, and inhibition of atrial fibrosis. MSKCC and comprehensive PMC reviews identify cardioprotection as a major pharmacological property of schisandrin B. No dedicated human cardiac trials have been published.

Cardiovascular protection is one of the most pharmacologically investigated activities of S. ningpoensis root. Studies in animal models have shown anti-ventricular remodelling, blood pressure reduction, antiplatelet aggregation, and anti-cardiomyocyte apoptosis effects. The compound angoroside C prevents ventricular remodelling and reduces blood pressure in rats.

SDG protects the myocardium by reducing oxidative stress, limiting cardiac hypertrophy, suppressing inflammatory apoptosis, and promoting angiogenesis in ischemic heart models. Pre-treatment with SDG reduced right ventricular hypertrophy, lipid peroxidation, and cardiac enzyme markers in PAH models. SDG also demonstrated cardioprotection against ischemia-reperfusion injury in hypercholesterolemic hearts through VEGF/eNOS-mediated neovascularization.

Selenium has been studied for cardiovascular protection given its role as an antioxidant via selenoproteins, with evidence from observational studies and RCTs. A meta-analysis of prospective studies demonstrated a nonlinear association between blood selenium and cardiovascular disease risk, with benefit observed within a narrow selenium range (55–145 µg/L). The KiSel-10 RCT showed that combined selenium and CoQ10 supplementation significantly reduced cardiovascular mortality in elderly Swedes with low baseline selenium. Evidence from trials is inconsistent across populations with differing baseline selenium status.

Selenoproteins reduce inflammation, prevent lipid oxidation, and inhibit platelet aggregation, providing a biological rationale for cardiovascular benefits of selenomethionine. However, the clinical evidence is mixed: the large SELECT trial (n=17,488) and a Cochrane review found no effect of selenium supplementation alone on cardiovascular event risk in selenium-replete men. A separate Swedish RCT found combined selenium plus CoQ10 significantly reduced cardiovascular mortality in selenium-deficient elderly individuals over 10–12 years.

Serratiopeptidase has been promoted for heart health based on its fibrinolytic and anti-atherosclerotic properties—the premise being that it could reduce fibrinous and lipid deposits in coronary arteries. A 2023 PMC preclinical study showed vascular anti-inflammatory effects. However, the Bhagat 2013 systematic review found no human RCTs for cardiovascular endpoints and concluded this evidence is insufficient.

Sesame supports heart health through clinically demonstrated reductions in blood pressure, LDL cholesterol, triglycerides, and inflammatory/oxidative markers — all major cardiovascular risk factors. Multiple meta-analyses of RCTs confirm these cardiometabolic benefits in hypertensive and diabetic populations. Sesame's polyunsaturated fatty acids, lignans, phytosterols, and antioxidant vitamins are the principal cardioprotective agents.

Shiitake's bioactive compounds—eritadenine, beta-glucans, lentinan, and ergothioneine—collectively support cardiovascular health through cholesterol lowering, anti-inflammatory, and antioxidant actions. Animal and in vitro data are substantial; human evidence is limited but directionally positive. Shiitake has a centuries-long history of use in East Asian medicine for cardiovascular benefit.

Silicon's role in maintaining elastin and collagen integrity in large arteries links it mechanistically to cardiovascular health. Population data show an inverse relationship between silicon in drinking water and cardiovascular mortality. Animal studies and one human RCT demonstrate benefits on arterial stiffness and blood pressure, though direct cardiac endpoints (myocardial infarction, heart failure) have not been tested in human trials.

A. julibrissin constituent flavonoids inhibit LDL oxidation, a key mechanism in atherosclerosis, and triterpenoid saponins have demonstrated cardioprotective activity in preclinical studies. TCM uses the herb for palpitations and heart spirit disturbance.

Silymarin shows indirect cardioprotective effects through improvements in lipid profiles, glycemic parameters, and diastolic blood pressure documented in a 2024 meta-analysis of 33 RCTs. Anti-inflammatory and antioxidant actions may reduce LDL oxidation and atherosclerotic risk. Human evidence for direct cardiac outcomes (myocardial infarction, cardiac events) remains limited to cardiometabolic risk factor studies.

Multiple clinical trials and meta-analyses confirm that sitostanol-based plant stanol esters reduce LDL cholesterol by 5–15% in hypercholesterolaemic populations, and this LDL reduction is projected to translate into meaningful reductions in coronary artery disease risk. Efficacy has been demonstrated in subjects with previous myocardial infarction taking statins. Typical doses of 1.5–3 g/day of plant stanols are used in enriched food products.

Cardioprotective activity is listed among confirmed pharmacological activities of P. hydropiper in peer-reviewed reviews, attributed to its flavonoid-rich phytochemistry (rutin, quercetin, kaempferol, isorhamnetin). Traditional use for cardiovascular conditions including angina is also documented. All evidence remains preclinical.

Polygonatum extracts have demonstrated lipid-lowering, anti-atherosclerotic, antioxidant, and mild cardiotonic properties in animal models and in vitro studies. A 2024 Springer review (PMC10759625) comprehensively documents cardioprotective activity of Polygonatum polysaccharides, flavonoids, and saponins. Human clinical evidence is sparse.

Oxymatrine from S. flavescens has been studied for cardioprotective and anti-arrhythmic effects in preclinical models. Flavonoids from S. japonica improve circulation, reduce platelet aggregation, and lower oxidative stress relevant to cardiovascular health. Multiple pharmacological reviews confirm cardiovascular applications of Sophora-derived compounds.

Soy protein (≥25 g/day) reduces LDL cholesterol by approximately 4–10% in clinical trials, supporting a heart health claim once authorized by the FDA. Soy isoflavones also improve endothelial function and may modestly lower blood pressure in hypertensive individuals. The AHA recognizes soy foods' overall cardiovascular benefit through favorable nutrient composition.

Soy isoflavones have been studied extensively for cardiovascular risk reduction. A 2021 meta-analysis in postmenopausal women found modest but significant decreases in total cholesterol and increases in HDL. Observational evidence links higher soy isoflavone intake with reduced CVD risk.

Soy foods and protein have been associated with cardiovascular benefit, leading to a 1999 FDA health claim linking ≥25 g/day soy protein with reduced coronary heart disease risk. The overall direct benefit of soy protein or isoflavone supplements on cardiovascular outcomes is now considered modest, but soy foods' favorable macronutrient profile (high polyunsaturated fat, fiber, low saturated fat) supports cardiovascular health. Soy isoflavones may benefit heart health through multiple mechanisms beyond cholesterol-lowering including anti-inflammatory and antioxidant pathways.

Spinach's nitrate content lowers blood pressure and arterial stiffness via nitric oxide generation. Its folate lowers homocysteine, a cardiovascular risk factor. Observational studies link vegetable nitrate intake to lower incident CVD. Spinach's antioxidants, fiber, and potassium also contribute to cardiometabolic protection.

Multiple RCTs and meta-analyses demonstrate spirulina reduces triglycerides, total cholesterol, and LDL while raising HDL, and lowers blood pressure in hypertensive patients — key cardiovascular risk factors. A 2025 systematic meta-analysis of RCTs confirmed consistent positive clinical outcomes for cardiovascular risk reduction. Phycocyanin reduces oxidative damage to endothelial cells and protects against doxorubicin-induced cardiotoxicity in preclinical models.

SPMs play documented roles in cardiac inflammation resolution, myocardial ischemia-reperfusion injury, and atherosclerosis. Preclinical studies show SPMs reduce infarct size and promote myocardial repair. Human translational studies demonstrate reduced SPM levels in cardiovascular disease patients and that omega-3 supplementation can partially restore SPM biosynthesis. The SPM:LTB4 ratio in human saliva predicts vascular disease risk.

Squalene has been investigated for cardiovascular risk via lipid modulation, antioxidant protection of lipoproteins, and anti-inflammatory mechanisms. A systematic review identified three human studies with mixed outcomes. One positive RCT showed cholesterol/LDL reduction; others showed no lipid effect. Squalene's antioxidant inhibition of LDL oxidation and NF-κB-driven vascular inflammation represents the strongest mechanistic evidence.

Stevia's heart health relevance is primarily supported by its antihypertensive effects in RCTs and anti-atherosclerotic effects in animal models. Stevioside (10 mg/kg) reduced aortic plaque volume in obese insulin-resistant mice by lowering macrophage, lipid, and oxidized LDL content. Aqueous stevia extract inhibited LDL oxidation in vitro, a key step in atherosclerosis pathogenesis.

Human RCT evidence supports an antihypertensive effect of higher-dose stevioside in mild hypertension, and in vitro/animal evidence suggests atherosclerotic plaque stabilization and cardiac oxidative protection. Steviol glycosides also show non-significant favorable trends on multiple cardiometabolic risk markers.

Multiple RCTs and a meta-analysis link strawberry consumption to improvements in cardiovascular risk markers including LDL cholesterol, CRP, LDL particle size, insulin resistance, and endothelial function. The Iowa Women's Health Study found a significant inverse association between strawberry intake and cardiovascular mortality over 16 years of follow-up in nearly 34,500 postmenopausal women. Strawberry polyphenols upregulate endothelial nitric oxide synthase and reduce lipid peroxidation.

Sulforaphane protects cardiovascular health via Nrf2 activation, NF-κB inhibition, reduced oxidized LDL, improved endothelial function, and decreased triglycerides. Human RCTs in T2DM patients demonstrate improvements in cardiovascular risk biomarkers. Preclinical evidence shows atherosclerosis attenuation.

Sunflower seed oil reduces cardiovascular risk biomarkers including LDL cholesterol, triglycerides, and coagulation factor VIIc in human RCTs. A review of 13 studies found the highest linoleic acid intakes associated with a 15% lower risk of heart disease events and 21% lower cardiovascular mortality. Helianthus annuus leaf extract has also shown cardioprotective effects in atherosclerosis/MI animal models.

Clinical evidence supports that high-oleic sunflower oil, when substituted for saturated fats, can reduce LDL cholesterol and lower coronary heart disease risk. The American Heart Association has reviewed studies confirming linoleic acid—abundant in sunflower oil—reduces coronary heart disease risk. Effect sizes are modest and results vary by oil variety (high-oleic vs. standard linoleic).

Ligusticum chuanxiong demonstrates documented pharmacological effects on myocardial ischemia, coronary vasodilation, and cardioprotection. TMP has been studied in patients with acute coronary syndrome, and CX-containing formulas are used clinically in China for cardiac conditions. Animal model studies show protective activity against isoproterenol-induced myocardial ischemia.

Taurine has substantial clinical and mechanistic evidence supporting its role in heart health. It is one of the most abundant free amino acids in cardiac tissue and has been shown in multiple randomized controlled trials to improve cardiac function, lower blood pressure, and enhance exercise capacity in heart failure patients. A 2024 meta-analysis of RCTs confirmed significant reductions in heart rate, systolic/diastolic blood pressure, and improved left ventricular ejection fraction with taurine supplementation.

Multiple clinical studies and reviews support Terminalia arjuna bark's cardioprotective role across heart failure, coronary artery disease, and ischemic cardiomyopathy. A double-blind RCT in refractory heart failure patients found clinically meaningful improvement in cardiac performance. Reviews consistently identify anti-ischemic, antioxidant, and inotropic mechanisms.

In a 12-week pilot RCT (n=11 dyslipidemic subjects), THIAA+niacin treatment produced a statistically significant and clinically relevant improvement in flow-mediated vasodilation compared to placebo, with improvements in total cholesterol, LDL-C, and uric acid. THIAA inhibits monocyte-endothelial inflammatory interactions directly implicated in atherosclerosis development.

T. cordifolia demonstrated antiarrhythmic and cardioprotective activity in rat models, normalizing ECG, reducing arrhythmia-induced heart rate changes, and modulating calcium/sodium/potassium levels. Diterpenoid compounds from T. cordifolia exhibit cardioprotective properties in preclinical research.

TMG's primary cardiac relevance is reducing homocysteine, a biomarker robustly associated with coronary artery disease and stroke risk. FDA-approved prescription betaine (Cystadane) treats homocystinuria, where uncontrolled homocysteine causes severe accelerated cardiovascular disease. For general populations, trials show homocysteine lowering but no proven reduction in hard cardiac events, and lipid-raising effects at higher doses introduce an offsetting risk.

Tocotrienols have demonstrated cardioprotective effects in clinical trials including lipid-lowering, anti-inflammatory cytokine reduction, and endothelial support. A review comparing tocotrienols to tocopherols found superior antioxidant activity and greater cardiovascular biomarker improvements. Tocotrienols are associated with reduced pro-inflammatory cytokines linked to cardiovascular disease.

Multiple meta-analyses of clinical trials show tomato and lycopene consumption is associated with reduced cardiovascular disease risk, lower stroke incidence, and improved cardiac biomarkers. A 2017 meta-analysis found high lycopene intake linked to a 14% lower CVD risk and 26% lower stroke risk. Tomato intake improves endothelial function and reduces LDL oxidation, key processes in heart disease development.

GGOH is an upstream precursor for CoQ10, which is concentrated in cardiac tissue and essential for myocardial energy production. By boosting endogenous CoQ10 synthesis, GGOH may support cardiac energy metabolism and reduce oxidative stress in the heart. GGOH also contributes to vitamin K2 (MK-4) synthesis, which regulates arterial calcification, a key cardiovascular risk factor.

Trans-pterostilbene modulates LDL receptor expression, reduces oxidative stress in cardiomyocytes, inhibits ACE, and upregulates nitric oxide synthase—key mechanisms relevant to cardiac protection. The primary human trial showed significant blood pressure reduction. Preclinical studies support protection against cardiomyocyte injury.

Trichosanthis Fructus is documented in the Chinese Pharmacopoeia and modern clinical practice as a treatment for angina, cardiac failure, myocardial infarction, and arrhythmia during AMI reperfusion. Pharmacological studies confirm protection against myocardial ischemia, calcium antagonism, endothelial cell protection, anti-hypoxic activity, and inhibition of platelet aggregation. Pericarpium Trichosanthis injection is clinically used for cardiovascular disease management in China.

Triphala reduces LDL-cholesterol, total cholesterol, and triglycerides in human clinical trials, and has demonstrated cardiotonic effects in preclinical models. A 2021 systematic review of 12 RCTs (749 patients) found significant lipid lowering in 6 studies. Its cardiovascular benefits are mechanistically linked to HMG-CoA reductase inhibition and antioxidant protection of the myocardium.

Clinical trial and meta-analytic evidence supports curcumin's benefit for cardiovascular health markers, including reductions in LDL cholesterol, triglycerides, blood pressure, and inflammatory markers. A 2025 Nature Scientific Reports RCT in diabetic patients with ASCVD risk found curcumin significantly reduced SBP, DBP, LDL-C, and TNF-α while raising HDL-C. Traditional use in Ayurveda also supports heart-protective use.

CoQ10/ubiquinol is one of the most clinically studied supplements for heart health, with evidence across heart failure, hypertension, and statin-associated myopathy. The Q-SYMBIO RCT (n=420 heart failure patients, 300 mg/day CoQ10) showed significant reductions in major adverse cardiovascular events. Ubiquinol is the preferred form in advanced heart failure due to its superior absorption over ubiquinone.

UA has demonstrated cardioprotective effects in preclinical models including diabetic cardiomyopathy and heart failure, and a human RCT found that 1 g/day UA for 4 months reduced plasma ceramide levels—a cardiovascular biomarker. A small pilot RCT in heart failure with reduced ejection fraction found no significant echocardiographic improvements, though the trial was likely underpowered.

Vanadium compounds have demonstrated cardioprotective effects in animal and preclinical models of myocardial ischemia/reperfusion injury, cardiac hypertrophy, and hypertension. The mechanism involves Akt signaling activation via PTP inhibition. No controlled human clinical trials specifically targeting heart disease outcomes have been completed.

Thiamine deficiency is a direct, well-documented cause of heart failure (wet beriberi), and cardiac function dramatically improves with thiamine repletion. Even sub-clinical thiamine insufficiency is associated with increased risk of heart failure in outpatient cardiology populations. Clinical trials have assessed thiamine supplementation in chronic heart failure.

Vitamin B12 is involved in homocysteine metabolism, and elevated homocysteine is epidemiologically associated with increased cardiovascular disease (CVD) risk. However, clinical trials and meta-analyses — including a Cochrane Review of 15 studies in over 71,000 participants — have consistently found that B12 supplementation does not reduce heart attacks, CVD events, or all-cause mortality. Mendelian randomization data likewise show no causal association between genetically predicted B12 levels and CVD. The link is scientifically studied but the supplementation hypothesis has not been validated.

Niacin (vitamin B3) has an extensively studied but complex and evolving relationship with heart health. High-dose nicotinic acid robustly raises HDL cholesterol and lowers LDL cholesterol and triglycerides, and early trials showed cardiovascular benefit. However, two large modern RCTs (AIM-HIGH and HPS2-THRIVE) found no incremental reduction in cardiovascular events when niacin was added to statin therapy, and recent research identifies a niacin metabolite (4PY) as a potential promoter of vascular inflammation. High-dose niacin is no longer routinely recommended for cardiovascular risk reduction.

The vitamin B5 derivative pantethine has been studied in multiple RCTs and shown to favorably alter lipid profiles in individuals at cardiovascular risk. Effects include reductions in LDL, total cholesterol, and triglycerides, and increases in HDL. The NIH ODS acknowledges these findings from both a 2005 review and more recent North American trials.

Vitamin B6 plays a mechanistic role in homocysteine metabolism via the transsulfuration pathway, and low plasma B6 levels are associated with elevated cardiovascular disease risk in observational studies. However, large randomized controlled trials (NORVIT, WENBIT, HOPE-2, Women's Antioxidant Cardiovascular Study) have consistently failed to show that B6 supplementation reduces cardiovascular events, even when it lowers homocysteine levels. The relationship is scientifically active but the therapeutic evidence for supplementation remains inconclusive.

Vitamin B9 (folate) has well-documented mechanistic and clinical links to cardiovascular health, primarily through lowering plasma homocysteine, improving endothelial function, and reducing stroke risk. A meta-analysis of 30 RCTs (82,334 participants) published in the Journal of the American Heart Association found a 10% lower stroke risk and 4% lower overall CVD risk with folic acid supplementation. However, benefits are most evident in folate-deficient populations or those without pre-existing CVD; in folate-replete populations, supplementation generally shows no added cardiovascular benefit. Folate also exerts homocysteine-independent effects on vascular function via nitric oxide pathways.

There is a substantive body of human clinical evidence linking vitamin C to cardiovascular health, primarily through its antioxidant and endothelial-function mechanisms. Observational data show inverse associations between vitamin C status and cardiovascular risk, while randomized controlled trials demonstrate modest reductions in blood pressure. However, major clinical trials have not consistently shown that vitamin C supplementation reduces hard cardiovascular endpoints, and overall evidence quality remains mixed.

Extensive observational data consistently links low serum 25-hydroxyvitamin D with increased risk of hypertension, atherosclerosis, heart failure, and cardiovascular mortality. Biologically, vitamin D modulates cardiomyocyte calcium handling, endothelial function, vascular smooth muscle, inflammation, and the renin–angiotensin–aldosterone system. However, large randomized controlled trials—including the landmark VITAL trial (25,871 participants, 2,000 IU/day vitamin D3)—have not demonstrated that supplementation reduces major cardiovascular events. The overall picture is one of strong biological plausibility and consistent epidemiological association, but unproven causality from interventional evidence.

Vitamin D3 has an extensively studied relationship with cardiovascular health, supported by substantial epidemiological, mechanistic, and clinical trial data. Observational studies consistently link low vitamin D levels to higher risks of hypertension, atherosclerosis, heart failure, and myocardial infarction. Mechanistically, vitamin D3 modulates the renin–angiotensin system, endothelial function, inflammation, and cardiomyocyte calcium handling. However, large RCTs have generally not confirmed a significant reduction in major cardiovascular events with supplementation in unselected populations, and evidence strength remains mixed.

Vitamin E (primarily alpha-tocopherol) has been extensively studied for cardiovascular disease prevention due to its antioxidant and anti-inflammatory properties. Early epidemiological data suggested benefit, but the preponderance of large randomized controlled trials (HOPE, GISSI, ATBC, WHS, PHS II) found no significant reduction in major cardiovascular events with supplementation. Some trials even raised concern about potential harms such as increased heart failure risk. The American Heart Association does not endorse vitamin E supplements for CVD prevention.

Vitamin K, particularly vitamin K2 (menaquinone), supports heart health primarily by activating matrix Gla protein (MGP), a potent inhibitor of arterial calcification. Large observational studies link higher vitamin K2 intake to lower rates of coronary heart disease, aortic calcification, and cardiovascular mortality. Randomized controlled trial evidence is more mixed: some trials show attenuation of coronary artery calcification progression, while others show no significant benefit, especially in advanced kidney disease populations. Overall, the evidence base is scientific but not yet conclusive enough to establish definitive therapeutic dosing guidelines.

Wasabi's 6-MSITC demonstrates anti-atherosclerotic activity via endothelial Nrf2/HO-1 activation, antiplatelet effects, and reduction of cardiac inflammatory markers in animal models. In a rat metabolic syndrome model, wasabi attenuated acute inflammation in the heart and reduced lipid deposition in the liver. These effects collectively support a cardioprotective profile, though human trial data are lacking.

The Gill et al. (2007) crossover RCT demonstrated a ~10% reduction in blood triglycerides after 8 weeks of daily watercress consumption in healthy adults. Human studies also report LDL reductions with watercress supplementation. Watercress is additionally a source of dietary nitrates and antioxidant carotenoids, both associated with cardiovascular benefit in broader research.

Watermelon's bioactive compounds—L-citrulline, lycopene, and antioxidant vitamins—collectively support cardiovascular health by reducing blood pressure, improving lipid profiles, and decreasing oxidative stress. Clinical trials in overweight/obese adults show reductions in LDL cholesterol, triglycerides, and blood pressure with daily watermelon consumption.

Prospective cohort studies consistently associate whole-grain wheat consumption with reduced cardiovascular disease risk. An RCT found daily consumption of 3 portions of whole-grain foods significantly reduced systolic blood pressure in middle-aged adults, with modeled reductions in coronary artery disease and stroke risk. The Cochrane review of 9 RCTs found insufficient evidence from RCTs alone for cholesterol or clinical CVD event reduction.

Wheat germ contains phytosterols, fiber, vitamin E, and unsaturated fatty acids that have mechanistic plausibility for cardiovascular benefit. Human RCT evidence is mixed: a 2020 meta-analysis of RCTs found no significant effect on total cholesterol or triglycerides at low doses, but one RCT in T2DM patients found a modest reduction in total cholesterol with 20 g/day. The evidence base is limited and effect sizes are small.

Wheatgrass has documented lipid-lowering effects in a human RCT (total cholesterol, LDL, and triglycerides reduced), and animal studies show reductions in atherogenic lipoproteins. Chlorophyll and flavonoids contribute cardiovascular anti-inflammatory activity. Overall, preliminary human evidence supports a modest cardioprotective role.

Whey protein has multiple documented effects on cardiovascular risk factors including blood pressure reduction, LDL-cholesterol and triglyceride lowering, and improved endothelial function. A pilot clinical trial in heart failure patients showed whey supplementation significantly improved systemic microvascular function. These effects are attributed to ACE-inhibitory peptides, antioxidant action via glutathione, and favorable effects on lipid and glucose metabolism.

Brewer's yeast supplementation has demonstrated modest improvements in lipid profiles and blood pressure in human clinical trials, primarily in type 2 diabetic patients. GTF-chromium may reduce cholesterol and triglycerides, while yeast-derived peptides and minerals (potassium, magnesium) may modulate blood pressure. Evidence is preliminary and not yet sufficient for guideline-level recommendations.

Berberine from Yellow Root has multiple clinical trial-supported cardiovascular benefits including cholesterol reduction, potential blood pressure lowering, and anti-arrhythmic effects. A meta-analysis of 27 RCTs demonstrated significant lipid-lowering. Some clinical evidence supports berberine's ability to prevent endothelial dysfunction and arrhythmia. Yellow Root was traditionally used for heart complaints.

Human studies show yerba mate reduces blood pressure and some inflammatory markers associated with cardiovascular risk. A large prospective cohort found heavy YM drinkers had lower total cholesterol and LDL. Evidence is also documented in postmenopausal women showing reduced self-reported cardiovascular disease frequency with higher YM intake.

Cardiac protective effects of Zanthoxylum are demonstrated preclinically through anti-atherosclerotic, antihypertensive, and hypolipidemic actions in multiple animal models. Z. tessmannii extract protected heart tissue in hypertensive rat models; Z. heitzii extract prevented atherosclerotic plaque formation. No human cardiovascular outcome data exist.

Epidemiological studies and large cross-sectional analyses consistently link higher serum lutein/zeaxanthin levels with lower risks of coronary heart disease, stroke, and cardiovascular mortality, particularly in hypertensive adults. However, the AREDS2 randomized clinical trial found no significant reduction in hard cardiovascular endpoints (heart attack, stroke, CV death) from lutein+zeaxanthin supplementation in an older population. Current evidence is therefore strongest at the observational level.

Multiple clinical and epidemiological studies establish a meaningful link between zinc status and cardiovascular health. Low serum zinc is consistently associated with increased risk of coronary artery disease, heart failure, and adverse cardiac events. Zinc supplementation has been shown in meta-analyses of RCTs to improve key CVD risk factors — notably triglycerides, total cholesterol, and glycemic indices — though effects on blood pressure are inconsistent. The relationship is dose- and duration-dependent, with low-dose, long-duration supplementation appearing most beneficial.

In Eastern Europe and Asia, decoctions of asparagus rhizomes and roots have a long history of use for cardiovascular diseases. Asparagus is recognized in multiple national pharmacopoeias for cardiovascular indications. Preclinical data supports ACE-inhibitory, diuretic, antihypertensive, and hypolipidemic effects, but robust human clinical trial evidence for cardiovascular outcomes is lacking.

Biota seed is categorized in TCM as a Heart-nourishing herb, entering the Heart meridian and addressing Heart Yin and Blood deficiency. It is used in classical formulas targeting the Heart organ system for palpitations, restlessness, and anxiety. A pharmacological reference also notes documented anti-arteriosclerosis activity, though human evidence is absent.

Chrysanthemum has a documented traditional use for cardiovascular conditions including hypertension and angina in TCM. Preclinical data support vasodilatory, anti-atherosclerotic, and lipid-lowering effects. Human-level evidence is limited to small studies and traditional clinical application.

Commiphora mukul was traditionally used in Ayurveda for conditions resembling atherosclerosis, and guggulsterones have demonstrated antiplatelet and antioxidant effects in preclinical studies. Formal clinical evidence for cardiovascular endpoints (beyond lipids) is lacking.

Elderberry's polyphenols are associated with cardiovascular protection in epidemiological and animal research. A review-level association between elderberry anthocyanins and reduced cardiovascular risk is documented. No dedicated human RCTs specifically testing elderberry for cardiovascular outcomes exist, making this a traditional and review-supported connection.

In TCM theory, fritillary acts on the heart meridian, and historical texts mention it for calming the Liver and clearing the Heart. The genus Fritillaria review lists heart diseases among traditional uses. Preclinical blood rheology data exist for FTB but direct heart-protective human evidence is absent.

Traditional Ayurvedic and folk medicine records cite H. spicatum rhizome use for heart diseases. The plant is an ingredient in PADMA-28, a Tibetan polyherbal formula studied for cardiovascular indications. Rhizome use for 'heart diseases' and hypotensive properties are documented in traditional sources, with some preclinical support for blood pressure reduction.

Traditional Ayurvedic and Unani texts list cardiovascular disease among Boswellia's documented traditional indications. Anti-atherogenic activity has been demonstrated in animal models. Modern pharmacological overviews list anti-atherogenic and anticoronary plaque activities as properties, but robust human cardiovascular clinical trials are lacking.

T. cordifolia is classified as 'cardiovascular protective' in Ayurvedic tradition and multiple pharmacological reviews. Preclinical data demonstrate antiarrhythmic effects and lipid normalization. A human trial found it reduces exercise-induced blood pressure and heart rate. Traditional use for cardiac ailments is documented in classical texts.

Heart troubles are listed among traditional Ayurvedic uses of Malabar nut, and cardioprotective activity is cited in pharmacological reviews. The plant has been noted to have moderate hypotensive activity and cardiac depressant properties in traditional literature.

P. tenuifolia is classified as a cardiotonic in TCM and Japanese Kampo, and is used in formulas for palpitations and heart-kidney disharmony. Preclinical evidence documents antiarrhythmic and cardioprotective effects of PT extract in isolated heart ischemia-reperfusion models. No human cardiac trials exist.

Rosemary has traditional associations with heart health in European herbalism and demonstrates antithrombotic properties in human ex vivo testing. Its antioxidant and anti-inflammatory constituents may protect cardiovascular tissues from oxidative damage, though dedicated cardiac endpoint RCTs in humans are absent.

Baicalin from S. baicalensis has demonstrated cardioprotective effects in preclinical models of myocardial injury, heart failure, and drug-induced cardiotoxicity, operating via anti-inflammatory and antioxidant mechanisms. Herbal Reality notes clinical use of S. baicalensis in China for cardiovascular disease. Human cardiology RCTs with skullcap alone are absent.

Star of Bethlehem bulbs contain cardiac glycosides (convallatoxin, convalloside, rhodexin A) that act similarly to digoxin, slowing heart rate and increasing myocardial contractility. There is a documented traditional use for congestive heart failure (CHF), and preliminary 1950s–1960s human reports exist (Vogelsang, Can Med Assoc J 1955; J Am Geriatr Soc 1961; Waud, J Pharmacol Exp Ther 1954), but no modern controlled clinical trials have been conducted and the plant is formally classified as unsafe.

Swertia chirayita is traditionally described as a cardiostimulant and heart protectant in Ayurvedic and other traditional systems. Pharmacological reviews document cardiostimulant activity. No dedicated human clinical studies on cardiac outcomes have been conducted.

Tribulus has a long history of traditional use in TCM and Ayurveda for chest pain, heart-related problems, and coronary circulation. A Chinese clinical observation reported improved angina outcomes with TT saponins, and animal studies show cardioprotective and ACE-inhibitory effects, but robust human RCTs on general heart health are absent.